Antibodies against soluble BCMA

Monoclonal antibodies generated through a rabbit immunization campaign address the sensitivity and reliability issues in detecting sBCMA, ensuring accurate detection and monitoring of sBCMA-related diseases despite therapeutic interference.

JP7596260B2Active Publication Date: 2024-12-09AMGEN INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021516763
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-09-28
Filing Date
2019-09-27
Publication Date
2024-12-09
Estimated Expiration
2039-09-27

AI Technical Summary

Technical Problem

Existing detection systems for soluble BCMA (sBCMA) face challenges in reliability and sensitivity, particularly in the presence of therapeutic antibodies, necessitating a highly sensitive and reproducible method for detecting sBCMA in biological samples.

Method used

Development of monoclonal antibodies and antibody constructs that bind to sBCMA in the presence of therapeutic antibodies, utilizing a rabbit immunization campaign to generate antibodies with a diverse repertoire and high somatic hypermutation rate, enabling effective detection and quantification of sBCMA.

Benefits of technology

The developed antibodies provide stable and sensitive detection of sBCMA, even in the presence of therapeutic interference, facilitating accurate diagnosis, disease stratification, and monitoring of sBCMA-related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007596260000006
    Figure 0007596260000006
  • Figure 0007596260000007
    Figure 0007596260000007
  • Figure 0007596260000008
    Figure 0007596260000008
Patent Text Reader

Abstract

The present invention relates to antibodies that bind to soluble BCMA (sBCMA). Additionally, the present invention relates to detection systems comprising such antibodies. The antibodies or detection systems can be used to detect or quantitate sBCMA, diagnose sBCMA-associated diseases, stratify patients, monitor disease progression, and assess therapeutic response.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to antibodies that bind to soluble BCMA (sBCMA). Additionally, the present invention relates to detection systems comprising such antibodies. The antibodies or detection systems can be used to detect or quantitate sBCMA, diagnose sBCMA-associated diseases, stratify patients, monitor disease progression, and assess therapeutic response.

[0002] Incorporation by Reference of Electronically Submitted Materials The computer readable nucleotide / amino acid sequence listing submitted contemporaneously herewith is incorporated by reference in its entirety and identified as follows: 34,276 byte ASCII (text) file entitled "53500A_Seqlisting.txt", created on September 27, 2019. [Background technology]

[0003] Multiple myeloma (MM) is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal proteins in the blood or urine, and associated organ damage. Multiple myeloma (MM) accounts for nearly 2% of all cancers and 20% of hematological malignancies (SEER). Although multiple myeloma remains an incurable cancer, improvements in understanding the causes of myeloma in recent years have led to the development of novel treatments and improved survival rates. Treatments include molecular targeted therapies designed to inhibit signaling pathways that support neoplastic cell survival and proliferation. One such target is the B cell maturation antigen, which is often expressed at relatively high levels on malignant plasma cells compared to normal plasma cells and induces proliferation signals upon binding of the ligands APRIL and BAFF.

[0004] B-cell maturation antigen (BCMA, TNFRSF17, CD269) is a transmembrane protein that belongs to the TNF receptor superfamily. BCMA expression is selectively induced during late plasma cell differentiation and is absent in naive and memory B cells. BCMA binding to its ligands (B-cell activating factor (BAFF) and proliferation-inducing ligand (APRIL)) promotes the survival of bone marrow plasma cells and plasmablasts. BCMA does not maintain normal B-cell homeostasis, but is required for the survival of long-lived plasma cells. BCMA mRNA expression is highly elevated in malignant plasma cell disorders. In contrast, BCMA mRNA expression in normal tissues is very low and restricted to lymphoid tissues where normal long-lived plasma cells reside. It has been reported that BCMA protein expression is restricted exclusively to plasma cells, and to plasmablasts and long-lived plasma cells, and cannot be detected in other normal human tissues. BCMA is expressed at relatively high levels in the majority of malignant plasma cells compared to normal plasma cells in MM patients. Neither T cells, myeloid cells, nor CD34+ hematopoietic stem cells express BCMA. The selective expression of BCMA on the majority of malignant plasma cells makes it a very attractive target for antibody- and chimeric antigen receptor (CAR)-based therapy. BCMA-negative profiles for MM patients have been reported, suggesting that patient selection for targeted therapy may be necessary. Detection of BCMA may not be limited to protein expression. Recent studies have shown that changes in serum BCMA may be a biomarker for treatment response or disease progression in patients with MM.

[0005] BCMA can be shed from the cell surface and has been found in serum samples from multiple myeloma patients as well as healthy subjects. Recent publications have demonstrated that soluble BCMA (sBCMA) levels correlate with the percentage of plasma cells in bone marrow biopsies, clinical status, and can be tracked with changes in M ​​protein levels. In this study, healthy donors had median sBCMA blood concentrations similar to the median levels observed in patients with complete responses. Patients with smoldering multiple myeloma had higher concentrations, but patients with active untreated multiple myeloma had the highest levels. Progression-free survival was longer in patients with sBCMA levels below the median when compared to patients with levels above the median. Changes in sBCMA levels can be a rapid and reliable indicator of treatment efficacy for patients with MM. Soluble BCMA may be used to predict or monitor disease progression because this biomarker can be detected in patients with low tumor burden, non-secretory disease, and is not dependent on renal function. Summary of the Invention [Problem to be solved by the invention]

[0006] There is therefore a strong need to provide a reliable detection system for sBCMA in biological samples that is highly sensitive, reproducible and ideally provides consistent results even in the presence of potentially interfering therapeutic sBCMA binding molecules (e.g. antibodies or antibody constructs). [Brief description of the drawings]

[0007] [Figure 1A-C]Assay setups performed according to Example 1 are shown. Figure 1A shows the assay setup for testing potential interference of therapeutic anti-BCMA abs with BCMA detection / quantification ELISA kits. Figure 1B shows three different Octet formats for the use of capture and detection antibodies in screening XenoMouse® anti-BCMA hybridomas for binding to BCMA in the presence of therapeutic monoclonal anti-sBCMA antibodies. Figure 1C shows the assay setup for screening rabbit sera for sandwich with therapeutic anti-BCMA abs. [Diagram 2] Characterization of two rabbit monoclonal anti-sBCMA Abs (sBCMA-mAb1 and sBCMA-mAb2) for sandwiching with a therapeutic anti-BCMA Ab (Ther-Ab2) in an Octet assay (see Example 2a). [Diagram 3] Figure 2 shows the results of an Octet assay demonstrating that rabbit monoclonal anti-sBCMA-mAb3 can be sandwiched with sBCMA-mAb1 and the therapeutic anti-BCMA antibody Ther-Ab2 (see Example 2c). [Figure 4] Shown are the results of an Octet assay that confirms the results shown in FIG. 3 (see Example 2c). [Diagram 5] FIG. 1 shows the results of affinity determination of rabbit monoclonal anti-sBCMA sandwich mAbs (sBCMA-mAb1, -mAb2 and -mAb3) by Biacore (see Example 3). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0008] To generate antibody pairs to detect sBCMA, we screened approximately 400 XenoMouse® hybridomas that had been generated against BCMA and tested positive in an ELISA assay for binding to BCMA. However, screening of these XenoMouse® hybridomas in the presence of monoclonal antibodies that bind sBCMA did not identify any sandwich antibodies, even when testing different formats of using capture and detection antibodies (see FIG. 1B). Next, a rabbit immunization campaign was performed and rabbit sera were screened for sandwich with monoclonal antibodies that bind sBCMA. In this case, the advantages of using rabbits for antibody generation are: - Different antibody repertoires, different epitope spaces (no competition) - Robust immune response - Gene conversion based immune system, higher somatic hypermutation rate compared to rodents, leading to higher affinity.

[0009] The presence of three sandwich antibodies (out of a total of 226 rabbit antibodies against sBCMA) could be demonstrated. Two of these (sBCMA-mAb1 and sBCMA-mAb2) were shown to compete with each other for binding to sBCMA. They were both able to bind to sBCMA in the presence of a therapeutic anti-BCMA antibody construct. The antibody sBCMA-mAb3 was further shown to bind to sBCMA in the presence of both sBCMA-mAb1 and a therapeutic anti-BCMA antibody construct.

[0010] Thus, in one aspect, the invention provides a monoclonal antibody (or antibody construct) that binds soluble BCMA (sBCMA), where binding of the antibody (or antibody construct) to sBCMA occurs in the presence of a second monoclonal antibody (or antibody construct) that binds sBCMA. The invention also provides a monoclonal antibody (or antibody construct) that binds soluble BCMA (sBCMA) in the presence of a second monoclonal antibody (or antibody construct) that binds sBCMA.

[0011] Hereinafter, whenever the term "monoclonal antibody" (i.e., a monoclonal antibody that binds sBCMA) is used, this term is meant to also encompass an "antibody construct" or "antibody fragment", which are defined herein below. Furthermore, the definitions and specifications of a "monoclonal antibody (or antibody construct)" of the invention (i.e., a monoclonal antibody or antibody construct that binds sBCMA) set out below apply equally to any "first monoclonal antibody (or antibody construct)" of the invention and any "second monoclonal antibody (or antibody construct)" of the invention.

[0012] An "antibody" (sometimes also known as an immunoglobulin) is a protein that immunospecifically binds to a target. An antibody recognizes a unique target, called an antigen, by its variable region. An "antibody" can be of any immunoglobulin isotype, such as IgG (e.g., IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (e.g., IgA1 and IgA2 subtypes), IgM, and IgE. The term "antibody" can include, for example, monoclonal antibodies, chimeric antibodies, recombinant antibodies, deimmunized antibodies, affinity matured antibodies, humanized antibodies, and human antibodies as well as antibodies from other species (e.g., rodent, rabbit, mouse, rat, hamster, goat, etc.). An antibody can be derived from only a single source or can be "chimeric", i.e., different portions of the antibody (e.g., CDRs, framework regions, variable regions, constant regions) can be derived from two different antibodies. The definition of "antibody" according to the present invention includes full-length antibodies, and also includes camelid antibodies and other immunoglobulins produced by biotechnological or protein engineering methods or processes. Antibodies may also be produced in hybridomas.

[0013] An intact IgG antibody generally comprises two full-length heavy chains and two full-length light chains. The "light chain" comprises a variable region having one domain ("VL") and a constant region having one domain ("CL"). The variable region of the light chain is at the amino-terminus of the polypeptide. Light chains include kappa and lambda chains. The "heavy chain" comprises a variable region having one domain ("VH") and a constant region having three domains ("CH") in the case of an intact IgG antibody: CH1, CH2 and CH3. VH is at the amino-terminus of the polypeptide, the CH domains are at the carboxyl-terminus, and CH3 is located closest to the carboxy-terminus of the polypeptide.

[0014] In classical full-length antibodies or immunoglobulins, each light (L) chain is linked to a heavy (H) chain by one covalent disulfide bond, while the two H chains are linked to each other by one or more disulfide bonds depending on the H chain isotype. The heavy chain constant (CH) domain closest to the VH is usually called CH1. The constant ("C") domains are not directly involved in antigen binding, but exhibit various effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement activation (complement-dependent cytotoxicity, CDC). The Fc region of an antibody is the "tail" region of a classical antibody that interacts with cell surface receptors called Fc receptors and some proteins of the complement system. In IgG, IgA and IgD antibody isotypes, the Fc region is composed of two identical protein fragments derived from the second and third constant domains (CH2 and CH3) of the two heavy chains of the antibody. The Fc region of IgM and IgE contains three heavy chain constant domains (CH2, CH3 and CH4) in each polypeptide chain. The Fc region also contains part of the so-called "hinge" region held together by one or more disulfides and non-covalent interactions. The Fc region of naturally occurring IgG carries highly conserved N-glycosylation sites. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity.

[0015] It is envisaged that the monoclonal antibody of the present invention may be an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody or an IgA antibody. According to one embodiment, the monoclonal antibody is an IgG antibody, for example an IgG1 antibody, an IgG2 antibody, an IgG3 antibody or an IgG4 antibody. The isotype and subclass of the antibody may be rabbit (e.g. rabbit IgG, rabbit IgG1, etc.).

[0016] In the context of the present invention, the term "variable" refers to those portions of antibodies or immunoglobulin domains which exhibit variability in their sequence and which are responsible for determining the specificity and binding affinity of a particular antibody (i.e., the "variable regions"). Typically, a heavy chain variable region (VH) and a light chain variable region (VL) pair together to form a single antigen-binding site.

[0017] The variability is not uniformly distributed throughout the variable region of an antibody, but is concentrated in subdomains of each of the heavy and light chain variable regions. These subdomains are called "hypervariable regions" or "complementarity determining regions" (CDRs). The more conserved (i.e., less hypervariable) parts of the variable regions are called "framework" (FR) regions, which provide a scaffold in three-dimensional space for the six CDRs to form the antigen-binding surface. The heavy and light chain variable regions of naturally occurring antibodies each contain four FR regions (FR1, FR2, FR3, and FR4) that are primarily in a β-sheet configuration. Together with the CDRs, the FR regions form the following sequence in the variable heavy or variable light chain: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The hypervariable regions of each chain are held together in close proximity by framework regions and usually contribute, together with the hypervariable regions from the other chain, to the formation of the antigen-binding site (see Kabat et al., Sequences of Proteins of Immunological Interest. Bethesda, National Institute of Health. 1991).

[0018] The term "CDR" and its plural "CDRs" refer to the complementarity determining regions, three of which constitute the binding properties of the light chain variable region (CDR-L1, CDR-L2 and CDR-L3) and three of which constitute the binding properties of the heavy chain variable region (CDR-H1, CDR-H2 and CDR-H3). CDRs contain the majority of residues responsible for the specific interaction of an antibody (or antibody construct or binding domain) with an antigen, thus contributing to the functional activity of an antibody molecule, and CDRs are the primary determinants of antigen specificity. The exact definition of the boundaries and lengths of CDRs depends on various classification and numbering systems. Thus, CDRs may be referred to by Kabat, Chothia, contact or any other boundary definition, including the numbering systems described herein. Although the boundaries differ, each of these systems has some overlap in the parts that constitute the so-called "hypervariable regions" within the variable sequences. Thus, the definitions of CDRs according to these systems may differ in length and in the boundaries with respect to the adjacent framework regions. See, for example, Kabat (an approach based on interspecies sequence variability), Chothia (an approach based on crystallographic studies of antigen-antibody complexes) and / or MacCallum (Kabat et al., supra; Chothia et al., J.MoI.Biol, 1987, 196:901-917; and MacCallum et al., J.MoI.Biol, 1996, 262:732). Yet another standard for characterizing antigen-binding sites is the AbM definition used by Oxford Molecular's AbM antibody modeling software. See, for example, Protein Sequence and Structure Analysis of Antibody Variable Domains. In:Antibody Engineering Lab Manual (Ed.:Duebel, S. and Kontermann, R., Springer-Verlag, Heidelberg). Two residue identification techniques may be combined to define hybrid CDRs, as long as they define overlapping, but not identical, regions. However, the so-called Kabat numbering system is preferred.

[0019] Typically, CDRs form loop structures that can be classified as canonical structures. The term "canonical structure" refers to the main chain conformation that antigen-binding (CDR) loops adopt. Comparative structural studies have found that five of the six antigen-binding loops have only a limited repertoire of available conformations. Each canonical structure can be characterized by the torsion angle of the polypeptide backbone. Thus, corresponding loops between antibodies can have very similar three-dimensional structures, despite the high amino acid sequence variability in most of the loops (Chothia and Lesk, J.MoI.Biol., 1987, 196:901; Chothia et al., Nature, 1989, 342:877; Martin and Thornton, J.MoI.Biol, 1996, 263:800). Furthermore, there is a relationship between the loop structure adopted and the amino acid sequence surrounding it. The conformation of a particular canonical class is determined by the length of the loop and the amino acid residues present at key positions within the loop and within the conserved framework (i.e., outside the loop), and therefore assignment to a particular canonical class can be made based on the presence of these key amino acid residues.

[0020] The term "canonical structure" may also include considerations of the linear sequence of an antibody, for example, as classified by Kabat (Kabat et al., supra). The Kabat numbering scheme is a widely adopted standard for numbering the amino acid residues of antibody variable regions in a consistent manner, and is the preferred scheme applied in the present invention, as mentioned elsewhere herein. Additional structural considerations may also be used to determine the canonical structure of an antibody. For example, differences not fully reflected by the Kabat numbering system may be accounted for by the Chothia et al. numbering system and / or may be revealed by other techniques (e.g., crystallography and two- or three-dimensional computer modeling). Thus, a given antibody sequence may be classified into a canonical class that allows for the identification of appropriate class sequences, particularly (e.g., based on the desire to include various canonical structures in the library). The Kabat numbering system of antibody amino acid sequences and the structural considerations described by Chothia et al. (supra) and their significance for interpreting the canonical aspects of antibody structure are explained in the literature. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are known in the art. For a general overview of antibody structure, see Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, eds. Harlow et al., 1988.

[0021] The CDR3 of the light chain and especially the CDR3 of the heavy chain may constitute the most important determinant in antigen binding within the variable regions of the light and heavy chains. In some antibodies, antibody constructs or domains, the heavy chain CDR3 appears to constitute the main contact area between the antigen and the antibody. An in vitro selection scheme in which only the CDR3 is changed can be used to change the binding properties of the antibody or antibody construct / binding domain, or to determine which residues contribute to antigen binding. Thus, the CDR3 is typically the greatest source of molecular diversity within the antibody binding site. For example, the CDR-H3 can be as short as two amino acid residues or more than 26 amino acids.

[0022] The sequences of antibody genes after construction and somatic mutation are highly diverse, and these diversified genes are 10 It is predicted that these genes encode different types of antibody molecules (Immunoglobulin Genes, 2 nd ed., eds. Jonio et al., Academic Press, San Diego, CA, 1995). Thus, the immune system provides a repertoire of immunoglobulins. The term "repertoire" refers to at least one nucleotide sequence derived in whole or in part from at least one sequence encoding at least one immunoglobulin. The sequence may be generated by in vivo rearrangement of the V, D and J segments of the heavy chain and the V and J segments of the light chain. Alternatively, the sequence may be generated from a cell in response to, for example, an in vitro stimulus that causes the rearrangement. Alternatively, some or all of the sequence may be obtained by DNA splicing, nucleotide synthesis, mutagenesis and other methods (see, for example, U.S. Pat. No. 5,565,332). A repertoire may include only one sequence or may include multiple sequences, including those in a genetically diverse collection.

[0023] The antibodies (and antibody constructs) of the present invention are envisaged to be monoclonal. As used herein, an antibody or antibody construct referred to as "monoclonal" (mAb) is obtained from a population of substantially homogeneous antibodies / antibody constructs, i.e., the individual antibodies / antibody constructs contained within this population are identical (particularly with respect to their amino acid sequence), except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in minor amounts. Monoclonal antibodies / antibody constructs are highly specific, directed against a single epitope within an antigen, in contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (or epitopes). In addition to their specificity, monoclonal antibodies are advantageous in that they are synthesized by hybridoma culture and thus are not contaminated by other immunoglobulins. The modifier "monoclonal" indicates the nature of the antibody / antibody construct as being obtained from a substantially homogeneous population of antibodies / antibody constructs and should not be construed as requiring production of the antibody by any particular method.

[0024] For the preparation of monoclonal antibodies, any technique that provides antibodies produced by continuous cell line cultures may be used. For example, the monoclonal antibodies / antibody constructs used may be made by the hybridoma method first described by Koehler et al., Nature, 256:495 (1975), or may be made by recombinant DNA methods (see, for example, U.S. Pat. No. 4,816,567). Further examples of techniques for producing human monoclonal antibodies include the trioma technique, the human B-cell hybridoma technique (Kozbor, Immunology Today 4 (1983), 72) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc. (1985), 77-96).

[0025] The hybridomas may then be screened using standard methods such as enzyme-linked immunosorbent assay (ELISA) and surface plasmon resonance (BIACORE™) analysis to identify one or more hybridomas producing an antibody / antibody construct that immunospecifically binds to a particular antigen. Any form of related antigen may be used as the immunogen, for example recombinant antigen, naturally occurring form, chimeric antigen, any variant or fragment of the antigen as well as antigenic peptides thereof. Surface plasmon resonance as employed in the BIAcore™ system may be used to increase the efficiency of binding of phage antibodies / antibody constructs to epitopes of the target antigen (Schier, Human Antibodies Hybridomas 7 (1996), 97-105; Malmborg, J. Immunol. Methods 183 (1995), 7-13).

[0026] Another exemplary method for producing antibodies, antibody constructs or binding domains includes screening protein expression libraries (e.g., phage display libraries or ribosome display libraries). Phage display is described, for example, in U.S. Patent No. 5,223,409 to Ladner et al.; Smith (1985) Science 228:1315-1317; Clackson et al., Nature, 352:624-628 (1991); and Marks et al., J. Mol. Biol., 222:581-597 (1991).

[0027] In addition to using display libraries, the relevant antigens can be used to immunize non-human animals (e.g., rodents, such as mice, hamsters, rabbits, or rats). In one embodiment, the non-human animals contain at least a portion of a human immunoglobulin gene. For example, mouse strains deficient in mouse antibody production can be engineered with large fragments of the human Ig (immunoglobulin) loci. Hybridoma technology can be used to generate and select antigen-specific monoclonal antibodies derived from genes with the desired specificity. See, e.g., Xenomouse™, Green et al. (1994) Nature Genetics 7:13-21, U.S. Patent Application Publication No. 2003-0070185, WO 96 / 34096, and WO 96 / 33735.

[0028] Monoclonal antibodies can also be modified (e.g., humanized, deimmunized, chimerized) after they are obtained from non-human animals using recombinant DNA techniques known in the art. Examples of modified antibodies, constructs, or binding domains include humanized variants of non-human antibodies / antibody constructs, "affinity matured" antibody constructs or binding domains (see, e.g., Hawkins et al. J. Mol. Biol. 254, 889-896 (1992) and Lowman et al., Biochemistry 30, 10832-10837 (1991)), and antibody variants or mutants with altered effector functions (see, e.g., U.S. Pat. No. 5,648,260; Kontermann and Duebel (2010), supra; and Little (2009), supra).

[0029] In immunology, affinity maturation is the process by which B cells produce antibodies with increased antigen affinity during an immune response. Repeated exposure to the same antigen will cause the host to produce antibodies with successively higher affinities. As with natural prototypes, in vitro affinity maturation is based on the principle of mutation and selection. In vitro affinity maturation has been successfully used to optimize antibodies, antibody fragments, antibody variants, antibody constructs or binding domains. Random mutations are introduced within the CDRs using radiation, chemical mutagens or error-prone PCR. In addition, chain shuffling can increase genetic diversity. Usually, two or three rounds of mutation and selection using display methods such as phage display result in antibodies, antibody fragments, antibody variants, antibody constructs or binding domains with affinities in the low nanomolar range.

[0030] Amino acid sequence modification of the antibodies (or antibody constructs) described herein are also contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of the antibody. Amino acid sequence variants of the antibodies are prepared by peptide synthesis or by introducing appropriate nucleotide changes into a nucleic acid molecule encoding the antibody. All amino acid sequence modifications described below should result in an antibody that retains the desired biological activity (binding to sBCMA) of the unmodified parent molecule.

[0031] The term "amino acid" or "amino acid residue" typically refers to amino acids having art-recognized definitions, such as amino acids selected from the group consisting of alanine (Ala or A); arginine (Arg or R); asparagine (Asn or N); aspartic acid (Asp or D); cysteine ​​(Cys or C); glutamine (GIn or Q); glutamic acid (GIu or E); glycine (GIy or G); histidine (His or H); isoleucine (Ile or I); leucine (Leu or L); lysine (Lys or K); methionine (Met or M); phenylalanine (Phe or F); proline (Pro or P); serine (Ser or S); threonine (Thr or T); tryptophan (Trp or W); tyrosine (Tyr or Y); and valine (Val or V), although modified, synthetic or rare amino acids may be used as appropriate. There are essentially four different classes of amino acids, as determined by the various side chains: (1) Non-polar and neutral (uncharged): Ala, Gly, Ile, Leu, Met, Phe, Pro, Val (2) Polar and neutral (uncharged): Asn, Cys (slightly polar), Gln, Ser, Thr, Trp (slightly polar), Tyr (3) Acidic and polar (negatively charged): Asp and Glu (4) Basic and polar (positively charged): Arg, His, Lys.

[0032] Hydrophobic amino acids can be divided according to whether they have an aliphatic or aromatic side chain. Phe and Trp (very hydrophobic), Tyr and His (less hydrophobic) are classified as aromatic amino acids. Strictly speaking, aliphatic means that the side chain contains only hydrogen and carbon atoms. By this strict definition, amino acids with aliphatic side chains are alanine, isoleucine, leucine (also norleucine), proline and valine. The very short side chain of alanine means that it is not particularly hydrophobic, and proline has a unique geometry that gives it a special role in proteins. It is often convenient to consider methionine in the same category as isoleucine, leucine and valine, but methionine also contains a sulfur atom. The unifying theme is that these amino acids contain mostly unreactive and flexible side chains. The amino acids alanine, cysteine, glycine, proline, serine and threonine are often lumped together because of their small size. Gly and Pro can influence chain orientation.

[0033] Amino acid modifications include, for example, deletions of residues from, insertions of residues into, and / or substitutions of residues within the amino acid sequence of the monoclonal antibody (antibody construct). Any combination of deletions, insertions, and / or substitutions may be made to arrive at a final monoclonal antibody (antibody construct), provided that the final antibody retains the desired properties, such as the biological activity of the unmodified parent molecule (e.g., binding to sBCMA). Amino acid changes may also alter post-translational processes of the antibody, such as changing the number or position of glycosylation sites.

[0034] For example, in each of the CDRs, 1, 2, 3, 4, 5, or 6 amino acids may be inserted, deleted, and / or substituted (depending, of course, on the length of each of the CDRs), and in each of the FRs, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 25 amino acids may be inserted, deleted, and / or substituted. Amino acid sequence insertions also include N-terminal and / or C-terminal additions of amino acids ranging from, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 residues to a polypeptide length of more than 10 (e.g., 100 or more residues), as well as intrasequence insertions of single or multiple amino acid residues.

[0035] The most interesting sites for amino acid modification (particularly amino acid substitution) include the hypervariable regions of the heavy and / or light chains (particularly the individual CDRs), although FR changes in the heavy and / or light chains are also contemplated herein. Substitutions can be conservative substitutions as described herein. Preferably, depending on the length of the CDR or FR, respectively, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids can be substituted in the CDRs, and 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 25 amino acids can be substituted in the framework regions (FRs). For example, if a CDR sequence contains 6 amino acids, it is envisaged that 1, 2 or 3 of these amino acids are substituted. Similarly, if a CDR sequence comprises 15 amino acids, it is envisaged that one, two, three, four, five or six of these amino acids may be substituted.

[0036] A method useful for identifying specific residues or regions within a monoclonal antibody (antibody construct) that are preferred locations for mutagenesis is called "alanine scanning mutagenesis" and is described, for example, in Cunningham BC and Wells JA (Science. 1989 Jun 2;244(4908):1081-5). Here, residues or groups of residues within an antibody are identified (e.g., charged residues such as Arg, His, Lys, Asp and Glu) and replaced with neutral or non-polar amino acids (most preferably alanine or polyalanine) to affect the interaction of each amino acid with the epitope of the target protein. Alanine scanning is a technique used to determine the contribution of specific residues to the stability or function of a given protein. Alanine is used due to its non-bulky and chemically inert methyl functional group, despite mimicking the secondary structure preferences of many other amino acids. Sometimes, bulky amino acids such as valine or leucine can be used when conservation of size of the mutated residue is required. This technique can also be useful in determining whether the side chain of a particular residue plays an important role in biological activity. Alanine scanning is usually accomplished by site-directed mutagenesis or randomly by PCR library creation. In addition, computational methods have been developed to estimate thermodynamic parameters based on theoretical alanine substitutions. Data can be examined by IR / NMR spectroscopy, mathematical methods, bioassays, etc.

[0037] The amino acid positions that show functional sensitivity to substitution (e.g., as determined by alanine scanning) can then be refined by introducing further or other variants at or for the substitution site. Thus, while the site or region for introducing amino acid sequence variation is predetermined, the nature of the mutation itself need not be predetermined. For example, to analyze or optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis can be performed at the target codon or region, and the expressed monoclonal antibody / antibody construct variants are screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA with known sequence (e.g., M13 primer mutagenesis and PCR mutagenesis) are known. Mutants are screened, for example, using an assay for antigen (e.g., sBCMA) binding activity as described herein.

[0038] Generally, when amino acids are replaced in one or more or all of the CDRs of the heavy and / or light chain / variable region, it is envisaged that the so obtained "replaced" sequence is at least 60% or 65%, more preferably 70% or 75%, even more preferably 80% or 85%, particularly preferably 90% or 95% identical / homologous / similar to the "original" or "parent" CDR sequence. This means that the degree of identity / homology / similarity between the original and the replaced sequence depends on the length of the CDR. For example, a CDR having a total of 5 amino acids and containing one amino acid replacement is 80% identical to the "original" or "parent" CDR sequence, and a CDR having a total of 10 amino acids and containing one amino acid replacement is 90% identical to the "original" or "parent" CDR sequence. Thus, the replaced CDRs of the monoclonal antibody of the invention may have different degrees of identity to their original sequences, for example CDRL1 may have 80%, while CDRL3 may have 90% homology. The same considerations apply to the framework regions and to the VH and VL regions as a whole.

[0039] A "variant CDR" is a CDR that has specific sequence homology, similarity or identity to a parent CDR of the invention and shares a biological function with the parent CDR, for example, but not limited to, at least 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% of the specificity and / or activity of the parent CDR. Generally, the amino acid homology, similarity or identity between the individual variant CDRs is at least 60% relative to the parent sequences shown herein, more typically at least 65% or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, most preferably 95%, 96%, 97%, 98%, 99% and even higher, such as 100% homology, similarity or identity. The same applies to "variant VH" and "variant VL". According to one embodiment, the sequence variation within "variant VH" and / or "variant VL" does not extend to the CDRs. Thus, the present invention relates to a monoclonal antibody (or antibody construct) as defined herein comprising a VH sequence and a VL sequence that have a particular sequence homology / identity / similarity (see above) to the particular sequences defined herein (the "parental" VH and VL), wherein the CDR sequences are 100% identical to the particular CDR sequences defined herein (the "parental" CDRs).

[0040] Preferred substitutions (or replacements) are conservative substitutions. However, any substitution (including a non-conservative substitution or one or more from the "exemplary substitutions" listed in Table 1 below) is envisaged, as long as the monoclonal antibody (antibody construct) retains the ability to bind sBCMA and / or the CDR, FR, VH and / or VL sequences of this monoclonal antibody (antibody construct) have an identity to the extent of at least 60% or 65%, more preferably at least 70% or 75%, even more preferably at least 80% or 85%, particularly preferably at least 90% or 95% with the original or parent sequence.

[0041] Conservative substitutions (also referred to as conservative mutations or conservative substitutions) are amino acid substitutions that change a given amino acid to another amino acid with similar biochemical properties (e.g., charge, hydrophobicity, size). Conservative substitutions in proteins often have less effect on protein function than non-conservative substitutions. Conservative substitutions are shown in Table 1. Exemplary conservative substitutions are shown as "exemplary substitutions." If such substitutions result in a change in biological activity, more substantial changes can be introduced and the products screened for desired properties, as further described herein with respect to amino acid classes.

[0042] [Table 1]

[0043] Substantial modification of the biological properties of the monoclonal antibody (antibody construct) of the present invention is achieved by selecting substitutions that have significantly different effects on (a) the structure of the polypeptide backbone in the substituted region, such as a sheet or helix conformation, (b) the charge or hydrophobicity of the molecule at the target site, or (c) maintaining the bulk of the side chain. Non-conservative substitutions usually entail the exchange of one member of the above-defined amino acid classes (e.g., polar, neutral, acidic, basic, aliphatic, aromatic, small) for another class. Any cysteine ​​residue that is not involved in maintaining the correct conformation of the antibody may generally be substituted with serine to improve the oxidative stability of the antibody.

[0044] Sequence identity, sequence homology and / or sequence similarity of amino acid sequences can be determined using standard techniques known in the art (such as, but not limited to, the local sequence identity algorithm of Smith and Waterman, 1981, Adv. Appl. Math. 2:482, preferably using default settings, the sequence identity alignment algorithm of Needleman and Wunsch (J Mol Biol. 1970 Mar;48(3):443-53), the similarity search method of Pearson and Lipman (Proc Natl Acad Sci USA. 1988 Apr;85(8):2444-8), computerized implementations of these algorithms (GAP, BESTFIT, FASTA and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis), Devereux et al. (Nucleic Acids Res. 1984 Jan 11;12(1 Pt 1):387-95) or by visual inspection. Percent identity is assumed to be calculated by FastDB based on the following parameters: mismatch penalty of 1; gap penalty of 1; gap size penalty of 0.33; and joining penalty of 30. See also "Current Methods in Sequence Comparison and Analysis", Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp 127-149 (1988), Alan R. Liss, Inc.

[0045] One example of a useful algorithm is PILEUP. PILEUP uses progressive pairwise alignment to generate a multiple sequence alignment from a group of related sequences. It can also plot a tree showing the clustering relationships used to generate the alignment. PILEUP uses a simplification of the progressive alignment method of Feng and Doolittle (J Mol Evol. 1987; 25(4): 351-60), which is similar to the method described by Higgins and Sharp (Comput Appl Biosci. 1989 Apr; 5(2): 151-3). Useful PILEUP parameters include a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.

[0046] Another example of a useful algorithm is the BLAST algorithm described in Altschul et al. (J Mol Biol. 1990 Oct 5;215(3):403-10.); Altschul et al., (Nucleic Acids Res. 1997 Sep 1;25(17):3389-402); and Karlin and Altschul (Proc Natl Acad Sci USA. 1993 Jun 15;90(12):5873-7). A particularly useful BLAST program is the WU-Blast-2 program, which was obtained from Altschul et al., (Methods Enzymol. 1996;266:460-80). WU-Blast-2 uses several search parameters, most of which are set to the default values. Adjustable parameters are set to the following values: overlap span=1, overlap fraction=0.125, word threshold T)=II. The HSP S and HSP S2 parameters are dynamic values ​​and are established by the program itself depending on the composition of the particular sequence and the composition of the particular database in which the sequence of interest is searched; however, the values ​​can be adjusted to increase sensitivity.

[0047] An additional useful algorithm is Gapped BLAST as reported by Altschul et al. (Nucleic Acids Res. 1997 Sep 1;25(17):3389-402). Gapped BLAST uses the BLOSUM-62 substitution score; a threshold T parameter set to 9; a two-hit method to trigger ungapped extensions, imposing a cost of 10+k on k gap lengths; Xu set to 16 and Xg set to 40 for the database search step and 67 for the output step of the algorithm. Gapped alignments are initiated by a score corresponding to approximately 22 bits.

[0048] Consistent with this, the term "percent (%) nucleic acid sequence identity / homology / similarity" with respect to a nucleic acid sequence encoding a monoclonal antibody (antibody construct) identified herein is defined as the percentage of nucleotide residues in a candidate sequence that are identical with the nucleotide residues in the coding sequence of the antibody. One method of aligning two sequences and thereby determining their homology uses the BLASTN module of WU-Blast2 set to default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively. Generally, the nucleic acid sequence homology, similarity or identity between the nucleotide sequence encoding each variant CDR and the nucleotide sequences set out herein will be at least 60%, more typically at least 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% with even higher homology, similarity or identity of up to 100%. Again, the same applies to the nucleic acid sequences encoding the "variant VH" and / or "variant VL".

[0049] The term "antibody construct" refers to a molecule whose structure and / or function is based on that of an antibody (e.g., a full-length immunoglobulin molecule). Thus, an antibody construct immunospecifically binds to its target or antigen and / or comprises a domain comprising or derived from the heavy chain variable region (VH) and / or the light chain variable region (VL) of an antibody. An antibody construct according to the invention comprises the minimal structural requirements of an antibody that allows immunospecific target binding. This minimal requirement may be defined, for example, by the presence of at least three light chain CDRs (i.e., CDR1, CDR2 and CDR3 of the VL region) and / or three heavy chain CDRs (i.e., CDR1, CDR2 and CDR3 of the VH region), preferably all six CDRs. Thus, an antibody construct may be characterized by the presence of three or six CDRs in the binding domain, and the skilled person knows where (and in what order) these CDRs are located within the binding domain.

[0050] The term "antibody construct" according to the present invention may also include fragments of full-length antibodies such as VH, VHH, VL, (s)dAb, Fv, light chain (VL-CL), Fd (VH-CH1), heavy chain, Fab, Fab', F(ab')2 or "rIgG" (a "half antibody" consisting of a heavy and light chain). Antibody fragments may be generated by enzymatic or chemical cleavage of intact antibodies. Antibody constructs according to the present invention may also include modified fragments of antibodies, also referred to as antibody variants or antibody derivatives. Examples include, but are not limited to: scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, "minibodies" exemplified by structures as follows: (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2, multibodies (e.g. triabodies or tetrabodies) and single domain antibodies (e.g. nanobodies or single variable domain antibodies comprising only one variable region which may be VHH, VH or VL, which specifically binds to an antigen or target independent of other variable regions or domains). Further possible formats of the antibody constructs according to the invention are crossbodies, maxibodies, hetero-Fc constructs, mono-Fc constructs and scFc constructs, examples of which are described herein below.

[0051] Furthermore, the definition of the term "antibody construct" includes bivalent and multivalent / multivalent constructs as well as bispecific and multispecific / multi-specific constructs that specifically bind to two, three or more antigen structures via different binding domains. For example, if an antibody construct has two binding domains for one target and one binding domain for another target (e.g., CD3) or vice versa, the antibody construct may have a valency greater than the specificity, in which case the construct is trivalent and bispecific. In general, the term "bispecific" includes the meaning that the antibody construct binds to (at least) two different antigens.

[0052] Furthermore, the definition of the term "antibody construct" includes molecules consisting of only one polypeptide chain as well as molecules consisting of two, three, four or more polypeptide chains, which chains may be identical (homodimers, homotrimers or homooligomers) or different (heterodimers, heterotrimers or heterooligomers). Examples of the above identified antibodies and their fragments, variants, derivatives and antibody constructs derived therefrom are described, inter alia, in Harlow and Lane, Antibodies: A laboratory manual, CSHL Press (1988); Kontermann and Duebel, Antibody Engineering, Springer, 2nd ed. 2010; and Little, Recombinant Antibodies for Immunotherapy, Cambridge University Press 2009.

[0053] The term "binding domain" or "domain that binds to" in the context of the present invention characterizes a domain of an antibody / antibody construct that immunospecifically binds to / immunospecifically interacts with / immunospecifically recognizes an epitope on a target or antigen (herein sBCMA). The structure and function of a binding domain is based on the structure and / or function of an antibody (e.g., a full-length immunoglobulin molecule). Thus, a "binding domain" or "domain that binds to" may comprise the minimum structural requirement of an antibody that allows immunospecific target binding. This minimum structural requirement of a binding domain may be defined, for example, by the presence of at least three light chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VL region) and / or three heavy chain CDRs (i.e. CDR1, CDR2 and CDR3 of the VH region), preferably all six CDRs. A "domain that binds to" (or "binding domain") typically comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH), but need not comprise both, and may comprise only VH or VL. Fd fragments, for example, often retain some antigen-binding function of the intact antigen-binding domain.

[0054] Examples of "domains that bind to" (or "binding domains") or formats of antibody constructs include, but are not limited to, full length antibodies, fragments of full length antibodies (e.g., VH, VHH, VL), (s)dAb, Fv, light chain (VL-CL), Fd (VH-CH1), heavy chain, Fab, Fab', F(ab')2 or "rAb" (Fab')2. IgG" ("half antibodies"), antibody variants or antibody derivatives such as scFv, di-scFv or bi(s)-scFv, scFv-Fc, scFv-zipper, scFab, Fab2, Fab3, diabodies, single chain diabodies, tandem diabodies (Tandab's), tandem di-scFv, tandem tri-scFv, "minibodies" (selected from formats such as (VH-VL-CH3)2, (scFv-CH3)2, ((scFv)2-CH3+CH3), ((scFv)2-CH3) or (scFv-CH3-scFv)2), multibodies (e.g. triabodies or tetrabodies) and single domain antibodies (e.g. nanobodies or single variable domain antibodies which comprise only one variable region which may be VHH, VH or VL). Further examples of formats of a "domain that binds to" (or "binding domain") include: (1) an antibody fragment or antibody variant comprising a VL, a VH, a CL, and a CH1 (e.g., a Fab); (2) an antibody fragment or antibody variant comprising two linked Fab fragments (e.g., F(ab')2); (3) an antibody fragment or antibody variant comprising a VH and a CH1 (e.g., an Fd); (4) an antibody fragment or antibody variant comprising a VL and a CL (e.g., a light chain); (5) an antibody fragment or antibody variant comprising a VL and a VH (e.g., an Fv); (5) a dAb fragment having a VH domain (Ward et al., (1989) Nature 341:544-546); (6) an antibody variant comprising at least three isolated CDRs of the heavy and / or light chain; and (7) a single chain Fv (scFv).Exemplary embodiments of antibody constructs or binding domains according to the invention are described, for example, in WO 00 / 006605, WO 2005 / 040220, WO 2008 / 119567, WO 2010 / 037838, WO 2013 / 026837, WO 2013 / 026833, US Patent Application Publication Nos. 2014 / 0308285, 2014 / 0302037, WO 2014 / 144722, WO 2014 / 151910 and WO 2015 / 048272.

[0055] In scFv, the VH and VL regions are arranged in the order VH-VL or VL-VH (from N-terminus to C-terminus). It is envisaged that the VH and VL regions are connected via a linker, preferably a peptide linker. According to one embodiment, the VH region is located at the N-terminus of the linker and the VL region is located at the C-terminus of the linker. It is further possible that the two scFv domains of the antibody construct are connected via a linker, preferably a peptide linker. The antibody construct may, for example, comprise the domains in the order (from N-terminus to C-terminus) first domain-linker-second domain. The reverse order (second domain-linker-first domain) is also possible.

[0056] The linker is preferably a peptide linker, more preferably a short peptide linker. According to the present invention, a "peptide linker" comprises an amino acid sequence that connects the amino acid sequence of one domain of an antibody construct with another (variable and / or binding) domain (e.g., a variable domain or a binding domain). An essential technical feature of such a peptide linker is that it does not contain any polymerization activity. Suitable peptide linkers include those described in US Pat. Nos. 4,751,180 and 4,935,233 or WO 88 / 09344. Peptide linkers can also be used to add other domains, or modules, or regions (e.g., half-life extending domains) to the antibody / antibody construct of the present invention. In this context, a "short" linker has 2 to 50 amino acids, preferably 3 to 35, 4 to 30, 5 to 25, 6 to 20 or 6 to 17 amino acids. The linker between the two variable regions of one binding domain may have a different length (e.g., may be longer) than the linker between the two binding domains. For example, the linker between the two variable regions of one binding domain may have a length of 7 to 15 amino acids, preferably 9 to 13 amino acids, and the linker between the two binding domains may have a length of 3 to 10 amino acids, preferably 4 to 8 amino acids. It is further envisaged that the peptide linker is a glycine / serine linker. The majority of amino acids of the glycine / serine linker are selected from glycine and serine.

[0057] When a linker is used to connect two binding domains with different binding specificities, the linker is preferably of sufficient length and sequence to ensure that each of these domains can retain their different binding specificities independently of each other. In the case of a peptide linker connecting at least two binding domains (or two variable regions forming one binding domain) in an antibody construct, it is envisaged that the peptide linker comprises only a small number of amino acid residues (e.g., 12 or less amino acid residues). Thus, peptide linkers of 12, 11, 10, 9, 8, 7, 6 or 5 amino acid residues are preferred. Envisaged peptide linkers of less than 5 amino acids comprise 4, 3, 2 or 1 amino acid, where Gly-rich linkers are preferred. A "single amino acid" linker in the context of the "peptide linker" is Gly. Another example of a peptide linker is characterized by the amino acid sequence Gly4Ser or a polymer thereof (i.e. (Gly4Ser)x), where x is an integer equal to or greater than 1 (e.g., 2 or 3). The characteristics of said peptide linkers are known in the art and are described, for example, in Dall'Acqua et al. (Biochem. (1998) 37, 9266-9273), Cheadle et al. (Mol Immunol (1992) 29, 21-30) and Raag and Whitlow (FASEB (1995) 9(1), 73-80). Peptide linkers that do not promote any secondary structures are preferred. The linkage of said domains to each other can be provided, for example, by genetic engineering. Methods for preparing fused and operably linked bispecific single chain constructs and expressing them in mammalian cells or bacteria are known in the art (for example, WO 99 / 54440 or Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 2001).

[0058] According to one embodiment of the present invention, the antibody construct of the present invention that binds to sBCMA can be a "single chain antibody construct". The two domains of the Fv fragment, VL and VH, are encoded by separate genes, but they can be linked by an artificial linker (as described herein above) that allows them to be produced using recombinant methods as a single protein chain in which the VL and VH regions pair to form a monovalent molecule; see, for example, Huston et al. (1988) Proc. Natl. Acad. Sci USA 85:5879-5883). These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are evaluated for functionality in the same way as full-length antibodies or IgG. Thus, single chain variable fragments (scFv) are usually fusion proteins of the variable regions of the immunoglobulin heavy (VH) and light (VL) chains connected by a short linker peptide. This linker is usually glycine-rich for flexibility, and also serine- or threonine-rich for solubility, and may connect the N-terminus of the VH to the C-terminus of the VL, or vice versa. The protein retains the specificity of the original immunoglobulin despite the removal of the constant regions and the introduction of the linker.

[0059] Antibody constructs referred to as "single domain antibodies" contain one (monomeric) antibody variable region that is capable of selectively binding to a specific antigen, independent of other variable regions. The first single domain antibodies were engineered from heavy chain antibodies found in camels, which consisted of a V H The H fragment is called the V fragment. Cartilaginous fish also have heavy chain antibodies (IgNAR), and these heavy chain antibodies are called V fragments. NARSingle domain antibodies, called fragments, can be obtained. An alternative approach is to split the dimeric variable region from a common immunoglobulin into monomers, thus obtaining VH or VL as single domain Abs. Currently, most of the research on single domain antibodies is based on the heavy chain variable region, but nanobodies derived from light chains have also been shown to specifically bind to target epitopes. Examples of single domain antibodies are called sdAbs, nanobodies or single variable domain antibodies. Thus, a (single domain mAb)2 is composed of VH, VL, V H H and V NAR A monoclonal antibody construct is a monoclonal antibody construct composed of (at least) two single domain monoclonal antibody constructs individually selected from the group comprising: a) ...

[0060] According to one embodiment, the antibody or antibody construct that binds to sBCMA is in the form of one or more polypeptides or in the form of a protein. In addition to the proteinaceous portion, such a polypeptide or protein may include a non-proteinaceous portion (e.g., a chemical linker or chemical cross-linking agent, such as glutaraldehyde).

[0061] Peptides are short chains of amino acid monomers linked by covalent peptide (amide) bonds. Thus, peptides are classified in the broad chemical class of biological oligomers and polymers. The amino acids that are part of a peptide or polypeptide chain may be referred to as "residues" and numbered consecutively. All peptides, except cyclic peptides, have an N-terminal residue at one end of the peptide and a C-terminal residue at the other end. Oligopeptides consist of only a small number of amino acids (usually 2-20). Polypeptides are longer continuous unbranched peptide chains. Peptides are distinguished from proteins on the basis of size, and may be understood to include about 50 amino acids or less as an arbitrary criterion. Proteins usually consist of one or more polypeptides arranged in a biologically functional manner. Although the aspects of the experimental techniques applied to peptides versus polypeptides and proteins (e.g., details of electrophoresis, chromatography, etc.) differ, the size boundaries that distinguish peptides from polypeptides and proteins are not absolute. Thus, in the context of the present invention, the terms "peptide", "polypeptide" and "protein" may be used interchangeably, with the term "polypeptide" often being preferred.

[0062] Polypeptides may further form multimers (e.g., dimers, trimers and higher oligomers) consisting of multiple polypeptide molecules. The polypeptide molecules forming such dimers, trimers, etc. may be identical or not. The corresponding structures of such higher multimers are therefore referred to as homodimers or heterodimers, homotrimers or heterotrimers, etc. An example of a heteromultimer is an antibody or immunoglobulin molecule, which in its naturally occurring form consists of two identical light polypeptide chains and two identical heavy polypeptide chains. The terms "peptide", "polypeptide" and "protein" also refer to naturally modified peptides / polypeptides / proteins, where modification is achieved, for example, by post-translational modifications such as glycosylation, acetylation, phosphorylation and the like. A "peptide", "polypeptide" or "protein", as referred to herein, may also be chemically modified (e.g., pegylation). Such modifications are known in the art and are described herein below.

[0063] The terms "bind (specifically or immunospecifically) to", "recognize (specifically or immunospecifically) to" or "react (specifically or immunospecifically) with" mean, according to the present invention, that an antibody, antibody construct or binding domain interacts or (immuno)specifically interacts with a given epitope (antigen, here sBCMA) on a target molecule. This interaction or association occurs more frequently, more rapidly, of longer duration, with higher affinity, or any combination of the above, for an epitope on a particular target compared to an alternative substance (non-target molecule). However, due to sequence similarity between homologous proteins in different species, an antibody, antibody construct or binding domain that immunospecifically binds to a target (e.g., a human target) may cross-react with a homologous target molecule from a different species (e.g., a non-human primate). Thus, the term "specific / immunospecific binding" may include binding by an antibody, antibody construct or binding domain to an epitope in multiple species or to structurally related epitopes.

[0064] In the context of the present invention, the term "epitope" refers to a part or region of an antigen that is recognized / immunospecifically recognized by a binding domain, an antibody or an antibody construct. An "epitope" is antigenic, and therefore the term epitope may also be referred to as an "antigenic structure" or "antigenic determinant". The part of a binding domain, an antibody or an antibody construct that binds to an epitope is called a paratope. Specific binding is believed to be achieved by specific motifs in the amino acid sequences of the binding domain, the antibody or the antibody construct and the antigen. Thus, binding is achieved as a result of its primary, secondary and / or tertiary structure and as a result of potential secondary modifications of said structure. The site may simply bind to the antigen due to a specific interaction between the paratope and its antigenic determinant. In some cases, the specific interaction may instead or additionally trigger a signal, e.g. due to induction of a conformational change in the antigen, oligomerization of the antigen, etc.

[0065] Epitopes of protein antigens are classified into two categories based on their structure and interaction with the paratope: conformational epitopes and linear epitopes. Conformational epitopes are composed of discontinuous sections of the antigen's amino acid sequence. The epitope interacts with the paratope based on the three-dimensional surface features and shape or tertiary structure (folding) of the antigen. Methods for determining the conformation of an epitope include, but are not limited to, X-ray crystallography, two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy, and site-specific spin labeling and electron paramagnetic resonance (EPR) spectroscopy. In contrast, linear epitopes interact with the paratope based on their primary structure. Linear epitopes are formed by contiguous amino acid sequences from an antigen, typically comprising at least three or at least four amino acid sequences in a unique sequence, more usually at least five, or at least six, or at least seven, e.g., about 8 to about 10 amino acids.

[0066] A method for epitope mapping of BCMA is described below: a predefined region (usually a contiguous stretch of amino acids) within the extracellular domain of the human BCMA protein is exchanged / replaced with the corresponding region of BCMA of another species (e.g. mouse, however other species are conceivable as long as the antibody does not cross-react with that species). This human BCMA / mouse (or other species) BCMA chimera may be expressed on the surface of host cells (e.g. CHO cells). Binding of the antibody or antibody construct may be tested by FACS analysis. If binding of the antibody or antibody construct to the chimeric molecule is completely abolished or if a significantly reduced binding is observed, it may be concluded that the region of human BCMA removed from the chimeric molecule is relevant for immune specific epitope-paratope recognition. The reduction in binding is preferably at least 10%, 20%, 30%, 40% or 50%; more preferably at least 60%, 70% or 80%, most preferably 90%, 95% or even 100% (wherein binding to human BCMA is taken as 100%), compared to binding to human (wild type) BCMA. Alternatively, the epitope mapping analysis described above may be modified by introducing one or more point mutations into the sequence of BCMA. The point mutations may, for example, reflect differences between human BCMA and mouse (or other species) BCMA.

[0067] A further method for determining the contribution of specific residues of a target antigen to the recognition by an antibody, antibody construct or binding domain is alanine scanning (see, for example, Morrison KL & Weiss GA. Curr Opin Chem Biol. 2001 Jun;5(3):302-7), in which each residue to be analyzed is replaced with alanine, for example by site-directed mutagenesis. Alanine is used because it mimics the secondary structural features of many other amino acids, but is not bulky and has a chemically inert methyl functional group. Sometimes, bulky amino acids such as valine or leucine can be used when it is necessary to preserve the size of the mutated residue.

[0068] The interaction between a monoclonal antibody (or antibody construct) and an epitope of a target antigen implies that the variable region exhibits a recognizable or significant affinity for the epitope / target antigen (herein sBCMA) and generally does not exhibit significant affinity for proteins or antigens other than the target antigen (herein sBCMA) (notwithstanding cross-reactivity with, e.g., homologous targets from other species, as discussed above). "Significant affinity" refers to an affinity greater than or equal to about ≦10 -6 M. Preferably, the binding affinity is about ≦10 -7 M, ≦10 -8 M, ≦10 -9 M or ≦10 -10 Binding is considered specific when the affinity is less than or equal to M. Thus, it is envisioned that a monoclonal antibody (or antibody construct) of the invention has an affinity (KD) for sBCMA of about ≦10-7M, ≦10-8M, ≦10-9M or ≦10-10M. These values ​​are preferably measured in a surface plasmon resonance assay, such as a Biacore assay. See Example 3.

[0069] Whether a monoclonal antibody (or antibody construct) (immuno)specifically reacts with or (immuno)specifically binds to a target can be easily tested, for example by comparing the affinity of said antibody for a desired target protein or target antigen with the affinity of said antibody for a non-target protein or non-target antigen (herein a protein other than sBCMA). Preferably, a monoclonal antibody (or antibody construct) of the invention does not significantly bind to a protein or antigen other than sBCMA, unless any additional binding domains for additional targets have been deliberately introduced into the antibody / antibody construct of the invention. The term "does not significantly bind" means that a monoclonal antibody (or antibody construct) of the invention does not bind to a protein or antigen other than sBCMA. The antibody construct thus exhibits a reactivity with proteins or antigens other than sBCAM of <30%, preferably <20%, more preferably <10%, particularly preferably <9%, <8%, <7%, <6%, <5%, <4%, <3%, <2% or <1% (wherein binding to sBCMA is taken as 100%). "Reactivity" may for example be expressed as an affinity value (see above). It is envisaged that the monoclonal antibody (or antibody construct) of the invention does not bind or significantly bind to, or interact with, does not recognise, or does not immunospecifically bind to or interact with human BAFF-R and / or human TACI.

[0070] The monoclonal antibody (or antibody construct) of the invention may be an "in vitro generated antibody / antibody construct" and / or a "recombinant antibody / antibody construct". In the context of the present invention, the term "in vitro generated" refers to an antibody / antibody construct according to the above definition, in which all or part of the variable region (e.g. at least one CDR) has been generated by non-immune cell selection (e.g. in vitro phage display) on a protein chip or by any other method that allows testing a candidate amino acid sequence for its ability to bind to an antigen. Thus, the term preferably excludes sequences that have been generated simply by genome rearrangement in an animal's immune cells. It is envisaged that the antibody (antibody construct) can be generated or obtained by phage display or library screening methods or by grafting CDR sequences from existing (monoclonal) antibodies onto a scaffold. A "recombinant antibody / antibody construct" is an antibody / antibody construct that has been generated or created using (among other things) recombinant DNA technology or genetic engineering.

[0071] A preferred type of amino acid substitution variation of the monoclonal antibody (or antibody construct) of the invention involves the substitution of one or more residues in the hypervariable region of the parent antibody structure. Generally, the resulting variant selected for further development has improved biological properties compared to the parent antibody structure from which it was generated. A convenient method for generating such substitution variants involves affinity maturation using phage display. Briefly, several sites (e.g., 6-7 sites) in the hypervariable region are mutated to generate all possible amino acid substitutions at each site. The variants so generated are displayed in a monovalent manner from filamentous phage particles as fusions with the gene III product of M13 packaged within each particle. The phage-displayed variants are then screened for biological activity (e.g., binding affinity) as disclosed herein. Alanine scanning mutagenesis may also be performed to identify candidate hypervariable region sites (alteration candidates) that contribute significantly to antigen binding. Alternatively or additionally, analysis of a crystal structure of a complex between an antigen and an antibody / antibody construct or binding domain may be beneficial in identifying contact points between the binding domain of an antibody / antibody construct and its specific antigen. Such contact and adjacent residues are candidates for substitution by the techniques detailed herein. Once such variants are generated, a panel of variants may be subjected to screening as described herein, and antibodies, antigen-binding fragments thereof, antibody constructs or binding domains having superior properties in one or more relevant assays may be selected for further development.

[0072] The monoclonal antibodies (or antibody constructs) of the invention particularly include "chimeric" versions in which a portion of the heavy and / or light chain is identical or homologous to a corresponding sequence in an antibody from a particular species or belonging to a particular antibody class or subclass, and the remainder of the chain is identical or homologous to a corresponding sequence in an antibody from another species or belonging to another antibody class or subclass, as well as fragments or variants of such antibodies, so long as the remaining portions of the chain exhibit the desired biological activity (U.S. Pat. No. 4,816,567; Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)). Chimeric antibodies, chimeric antibody constructs or chimeric binding domains of interest herein include, for example, "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g., Old World Monkey, Ape, etc.) and human constant region sequences. Various techniques for producing chimeric antibodies or chimeric antibody constructs have been described (see, e.g., Morrison et al., Proc. Natl. Acad. ScL USA 81:6851, 1985; Takeda et al., Nature 314:452, 1985; U.S. Patent No. 4,816,567 to Cabilly et al.; U.S. Patent No. 4,816,397 to Boss et al.; European Patent Nos. 0171496 and 0173494 to Tanaguchi et al.; and British Patent No. 2177096 to Tanaguchi et al.).

[0073] "Humanized" monoclonal antibodies, variants or fragments thereof, antibody constructs, and binding domains are based on immunoglobulins of predominantly human sequence, which contain minimal sequence derived from non-human immunoglobulin. In most cases, humanized antibodies, variants or fragments thereof, antibody constructs, and binding domains are based on a human immunoglobulin (recipient antibody) in which residues from a hypervariable region or CDR are replaced by residues from a hypervariable region or CDR of a non-human species (donor antibody), such as a rodent (e.g., mouse, hamster, rat, or rabbit), having the desired specificity, affinity, capacity, and / or biological activity. In some instances, Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, as used herein, "humanized" antibodies, variants or fragments thereof, antibody constructs, and binding domains may also include residues that are not found in either the recipient antibody or the donor antibody. These modifications are made to further refine and optimize antibody performance. Humanized antibodies, variants or fragments thereof, antibody constructs and binding domains can also comprise at least a portion of an immunoglobulin constant region (e.g., Fc), typically that of a human immunoglobulin. For further details, see Jones et al., Nature, 321:522-525 (1986); Reichmann et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992).

[0074] Humanized antibodies, variants or fragments thereof, antibody constructs, and binding domains can be made by replacing sequences of the (Fv) variable region not directly involved in antigen binding with equivalent sequences from a human (Fv) variable region. Exemplary methods for producing such molecules are provided by Morrison (1985) Science 229:1202-1207; Oi et al. (1986) BioTechniques 4:214, and U.S. Patent Nos. 5,585,089, 5,693,761, 5,693,762, 5,859,205, and 6,407,213. These methods include isolating, manipulating, and expressing nucleic acid sequences that encode all or part of the immunoglobulin (Fv) variable region from at least one of the heavy or light chains. Such nucleic acids can be obtained from hybridomas (discussed above) and other sources that produce antibodies against a predetermined target. The recombinant DNA encoding the humanized antibody, variant or fragment thereof, antibody construct, or binding domain can then be cloned into an appropriate expression vector.

[0075] Humanized antibodies, variants or fragments thereof, antibody constructs and binding domains can also be produced using transgenic animals (e.g., mice) that express human heavy and light chain genes but lack the ability to express endogenous mouse immunoglobulin heavy and light chain genes. Winter describes an exemplary CDR grafting method that can be used to prepare the humanized molecules described herein (U.S. Pat. No. 5,225,539). All of the CDRs of a particular human sequence can be replaced with at least a portion of a non-human CDR, or only a portion of the CDRs can be replaced with a non-human CDR. It is sufficient to replace only as many CDRs as are necessary for the humanized molecule to bind a given antigen.

[0076] Humanized antibodies, variants or fragments thereof, antibody constructs or binding domains may be optimized by introducing conservative substitutions, consensus sequence substitutions, germline substitutions and / or back mutations. Such altered immunoglobulin molecules may be generated by any of several techniques known in the art (e.g., Teng et al., Proc. Natl. Acad. Sci. USA, 80:7308-7312, 1983; Kozbor et al., Immunology Today, 4:7279, 1983; Olsson et al., Meth. Enzymol., 92:3-16, 1982 and EP 239400).

[0077] According to one embodiment, the monoclonal antibody (or antibody construct) is "rabbit". The terms "rabbit antibody", "rabbit antibody construct" and "rabbit binding domain" include antibodies, antibody constructs and binding domains, respectively, having antibody-derived regions (e.g., variable regions or domains and constant regions or domains) that substantially correspond to rabbit germline immunoglobulin sequences known in the art. The rabbit antibody construct or rabbit binding domain of the invention may contain amino acid residues not encoded by rabbit germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs (particularly CDR3). The rabbit antibody, rabbit antibody construct or rabbit binding domain may have at least one, two, three, four, five or more positions replaced with amino acid residues not encoded by rabbit germline immunoglobulin sequences. The definitions of rabbit antibodies, rabbit antibody constructs and rabbit binding domains as used herein also contemplate complete rabbit antibodies, rabbit antibody constructs and rabbit binding domains that contain only non-artificial and / or genetically altered rabbit sequences of the antibody.

[0078] It is envisaged that the monoclonal antibody (or antibody construct) of the invention is an "isolated" or "substantially pure" antibody. "Isolated" or "substantially pure", when used to describe the antibodies described herein, means an antibody that has been identified, separated and / or recovered from components of its production environment. Preferably, the antibody is free or substantially free of association with all other components from its production environment. Contaminating components of the production environment (e.g., arising from recombinant transfected cells) are, for example, substances that may interfere with the diagnostic use of the antibody (or antibody construct), and may include enzymes, hormones and other proteinaceous or non-proteinaceous compounds. It is understood that an isolated or substantially pure antibody (or antibody construct) may represent 5% to 99.9% by weight of the total protein / polypeptide content in a given sample, depending on the circumstances. The desired antibody (or antibody construct) may be produced at significantly higher concentrations by using inducible or high expression promoters. This definition includes the production of antibodies (or antibody constructs) in a variety of organisms and / or host cells known in the art. In certain embodiments, antibodies are (1) purified to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) purified to homogeneity by SDS-PAGE under non-reducing or reducing conditions using Coomassie blue or, preferably, silver staining. Ordinarily, however, an isolated antibody or antibody construct will be prepared by at least one purification step.

[0079] The monoclonal antibodies (or antibody constructs) of the invention bind to soluble BCMA (sBCMA). "Soluble BCMA" is a cleavage fragment of membrane-bound BCMA. Cleavage occurs, for example, by secretases, and shed BCMA (sBCMA) is released from the cell surface. Soluble BCMA levels are usually elevated in MM patients compared to healthy individuals, but also in patients with other diseases. Furthermore, sBCMA levels in the serum of patients may correlate with disease status and prognosis. Levels of sBCMA may also be significantly reduced after successful treatment of diseases associated with BCMA overexpression or elevated sBCMA levels. It is envisaged that the sBCMA is human sBCMA. The amino acid sequence of the entire (membrane-bound) human BCMA molecule (B-cell maturation antigen, TNFRSF17, CD269) is shown in SEQ ID NO: 33, and the amino acid sequence of the extracellular domain of human BCMA is shown in SEQ ID NO: 34. This sequence also corresponds to shed or soluble BCMA. In other words, sBCMA is envisaged to have the amino acid sequence set forth in SEQ ID NO:34.

[0080] The term "binding occurs in the presence of" in the context of the present invention means that there is simultaneous binding of two (or more) antibodies (or antibody constructs) to the same target (herein sBCMA). In other words, the two (or more) antibodies (or antibody constructs) do not compete or do not significantly compete (with each other) for binding to the target (herein sBCMA). According to one embodiment, this can also mean that one monoclonal antibody (or antibody construct) binds to a different sBCMA epitope to that of a second monoclonal antibody or antibody construct (or the addition of a third antibody or antibody construct, see below).

[0081] According to one aspect of the invention, binding of a monoclonal antibody (or antibody construct) to sBCMA occurs in the presence of binding of a second monoclonal antibody (or antibody construct) to sBCMA, as well as in the presence of binding of a third antibody or antibody construct to sBCMA, which third antibody or antibody construct may be a therapeutic antibody or antibody construct that binds to the extracellular domain of BCMA.

[0082] In one embodiment of the invention, the third antibody or antibody construct binds to epitope cluster 3 of BCMA. More preferably, the third antibody or antibody construct binds to epitope cluster 3 of human BCMA. The amino acid sequence of epitope cluster 3 of human BCMA is shown in SEQ ID NO: 35. An antibody construct having a domain that binds to said epitope cluster 3 of BCMA is described in detail in WO2013 / 072406, the contents of which are incorporated herein by reference. This antibody construct was shown to have a very beneficial epitope / activity relationship. It is envisaged that the "third antibody or antibody construct" of the invention comprises a domain that binds to BCMA and comprises a VH region comprising VH-CDR1, VH-CDR2 and VH-CDR3, and a VL region comprising VL-CDR1, VL-CDR2 and VL-CDR3, as claimed in WO2013 / 072406. It is further envisaged that the third antibody or antibody construct comprises a domain that binds BCMA and comprises a VH region and / or a VL region as disclosed in the claims of WO2013 / 072406. It is also envisaged that the third antibody or antibody construct comprises a domain that binds BCMA and a domain that binds CD3 (e.g. human CD3, preferably CD3 epsilon or human CD3 epsilon) as disclosed and claimed in WO2013 / 072406. It is also envisaged that the third antibody or antibody construct binds to the same sBCMA epitope as the antibody defined and claimed in WO2013 / 072406 or competes for binding to sBCMA with the antibody defined and claimed in WO2013 / 072406.

[0083] Antibodies (or bispecific antibody constructs) against (human) CD3 or specifically against CD3 epsilon are known in the art, whose CDR, VH and VL sequences may serve as the basis for the second binding domain of the "first", "second" or "third" antibody / antibody construct of the invention. For example, Kung et al. reported in 1979 the development of OKT3 (Ortho Kung T3), the first mAb that recognizes CD3 (specifically the epsilon chain of CD3) on human T cells. OKT3 (muromonab) was the first mouse-derived monoclonal antibody available for therapy in humans. Recent anti-CD3 monoclonal antibodies include otelixizumab (TRX4), teplizumab (MGA031), foralumab and visilizumab, all of which target the epsilon chain of CD3. Bispecific antibody constructs against (cancer) targets and CD3 are also being developed and (pre)clinical tested, whose CD3 binding domains (CDR, VH, VL) may serve as the basis for the second binding domain of the first, second or third antibody / antibody construct of the invention, including but not limited to: blinatumomab, solitomab (MT110, AMG110), catumaxomab, duvortuxizumab, ertumaxomab, mosunetuzumab, FBTA05 (Bi20, TPBs05), CEA-TCB (RG7802, RO6958688), AFM11 and MGD006 (S80880). Other examples of CD3 binding domains are disclosed, for example, in U.S. Pat. Nos. 7,994,289 B2, 7,728,114 B2, 7,381,803 B1, and 6,706,265 B1.

[0084] It is further envisaged that the third antibody construct of the invention comprises a domain that binds BCMA as described herein, a domain that binds CD3 as described herein and a domain that provides for an extended half-life of the antibody construct. This latter domain may comprise two polypeptide monomers, each comprising a hinge, a CH2 domain and a CH3 domain, said two polypeptide monomers being fused together via a peptide linker. Such antibody constructs and HLE domains are described in detail in WO 2017 / 134134, the contents of which are incorporated herein by reference.

[0085] In a further embodiment, the "third antibody or antibody construct" is an antibody / antibody construct disclosed in WO 2014 / 089335 as having the following amino acid sequences: VH-CDR (SEQ ID NOs: 4-6), VL-CDR (SEQ ID NOs: 106-108), VH (SEQ ID NO: 206), VL (SEQ ID NO: 240) of WO 2014 / 089335. Thus, the third antibody or antibody construct may comprise a VH region comprising VH-CDR1 as shown in SEQ ID NO: 4, VH-CDR2 as shown in SEQ ID NO: 5, and VH-CDR3 as shown in SEQ ID NO: 6 of WO 2014 / 089335, and a VL region comprising VL-CDR1 as shown in SEQ ID NO: 107, VL-CDR2 as shown in SEQ ID NO: 107, and VL-CDR3 as shown in SEQ ID NO: 108 of WO 2014 / 089335. The third antibody or antibody construct may also comprise a VH region as set forth in SEQ ID NO: 206 of WO2014 / 089335 or a VL region as set forth in SEQ ID NO: 240 of WO2014 / 089335. The third antibody or antibody construct may also bind to the same sBCMA epitope as an antibody defined herein above or may also compete for binding to sBCMA with an antibody defined herein above (i.e. an antibody having a sequence cited from WO2014 / 089335).

[0086] It is envisaged that the monoclonal antibody / antibody construct of the invention comprises (a) a rabbit VH region, (b) a rabbit VL region, or (c) a rabbit VH region and a rabbit VL region. Furthermore, the entire monoclonal antibody may be a rabbit antibody. Thus, the variable region or the antibody / antibody construct is itself derived from a rabbit. The terms "rabbit antibody", "rabbit antibody construct", "rabbit binding domain" and "rabbit VH / VL region" include antibodies, antibody constructs, binding domains and VH / VL regions, respectively, that comprise antibody-derived regions (e.g., variable and constant regions) or domains that substantially correspond to rabbit germline immunoglobulin sequences known in the art. The rabbit antibody, rabbit antibody construct or rabbit binding domain of the invention may comprise amino acid residues not encoded by rabbit germline immunoglobulin sequences (e.g., mutations introduced by random or site-directed mutagenesis in vitro or by somatic mutation in vivo), for example in the CDRs (particularly CDR3). The definitions of rabbit antibody, rabbit antibody construct and rabbit binding domain as used herein also contemplate complete rabbit antibodies, antibody constructs, VH / VL regions and binding domains that comprise only non-artificial and / or genetically modified rabbit sequences of the antibody. These can be obtained, for example, by rabbit immunization campaigns using standard techniques known in the art. The monoclonal antibodies of the invention can also comprise rabbit VH and / or rabbit VL regions and antibody constant regions, for example rabbit constant regions (e.g., the exemplary rabbit heavy chain constant region of SEQ ID NO: 31 or the exemplary rabbit light chain constant region of SEQ ID NO: 32) or constant regions from other species (human, mouse, rat, hamster, goat, etc.) depending on the requirements and design of the sBCMA detection system.

[0087] According to one embodiment of the invention, the monoclonal antibody or antibody construct comprises: a) comprising a VH region comprising VH-CDR1 shown in SEQ ID NO: 1, VH-CDR2 shown in SEQ ID NO: 2, and VH-CDR3 shown in SEQ ID NO: 3, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 4, VL-CDR2 shown in SEQ ID NO: 5, and VL-CDR3 shown in SEQ ID NO: 6; b) a VH region comprising a VH-CDR1 represented by SEQ ID NO: 11, a VH-CDR2 represented by SEQ ID NO: 12, and a VH-CDR3 represented by SEQ ID NO: 13, and a VL region comprising a VL-CDR1 represented by SEQ ID NO: 14, a VL-CDR2 represented by SEQ ID NO: 15, and a VL-CDR3 represented by SEQ ID NO: 16; or c) A VH region comprising VH-CDR1 shown in SEQ ID NO: 21, VH-CDR2 shown in SEQ ID NO: 22, and VH-CDR3 shown in SEQ ID NO: 23, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 24, VL-CDR2 shown in SEQ ID NO: 25, and VL-CDR3 shown in SEQ ID NO: 26.

[0088] It is further envisaged that the monoclonal antibodies of the invention bind to the same sBCMA epitope as an antibody of a), b) or c) above, or compete for binding to sBCMA with an antibody of a), b) or c) above.

[0089] Whether an antibody, antibody construct or binding domain binds to the same epitope of sBCMA (or the extracellular domain of BCMA) as another given antibody, antibody construct or binding domain can be determined by various analyses (e.g. epitope mapping with chimeric or mutated BCMA molecules, e.g. as described in WO 2013 / 072406). Other methods of determining epitopes (e.g. alanine scanning) are described herein (see, e.g. Morrison KL & Weiss GA. Curr Opin Chem Biol. 2001 Jun;5(3):302-7), in which each residue in the target amino acid sequence to be analyzed is replaced with alanine, e.g. by site-directed mutagenesis. Alanine is used due to its non-bulky and chemically inert methyl functional group, despite mimicking the secondary structure preferences of many other amino acids. Sometimes, bulky amino acids such as valine or leucine can be used when size conservation of the mutated residue is required. This method of introducing systematic mutations of amino acids into the sequence of a target protein and testing the binding of an antibody to each mutant protein to identify the amino acids that contain the epitope is also called "site-directed mutagenesis". Other methods available for mapping antibody epitopes on target antigens are high-throughput shotgun mutagenesis epitope mapping, cross-linking coupled mass spectrometry, X-ray co-crystallography, cryo-electron microscopy and hydrogen-deuterium exchange.

[0090] Whether an antibody or antibody construct competes with another given antibody or antibody construct for binding to an antigen (e.g., BCMA or sBCMA) can be measured in a competitive assay, such as a competitive ELISA. Avidin-conjugated microparticles (beads) can also be used. Similar to an avidin-coated ELISA plate, each of these beads can be used as a substrate on which an assay can be performed when reacted with a biotinylated protein. The antigen is coated onto the beads, then pre-coated with the first antibody. A secondary antibody is added and any further binding is determined. The reading is performed by flow cytometry. A cell-based competitive assay can be used, using either cells naturally expressing BCMA or cells stably or transiently transformed with BCMA. Furthermore, example 2b) of the present invention describes an Octet competition assay that can also be used to determine the competition between two antibodies / antibody constructs for binding to sBCMA. The term "compete for binding" in this context means that there is at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% competition between two test antibodies as determined by any one of the assays disclosed above.

[0091] According to one embodiment of the invention, the monoclonal antibody comprises: a) comprises a VH region set forth in any one of SEQ ID NOs: 7, 17, or 27; b) comprises a VL region as set forth in any one of SEQ ID NOs: 8, 18, or 28; c) comprising a VH region as set forth in SEQ ID NO: 7 and a VL region as set forth in SEQ ID NO: 8; d) comprising a VH region as set forth in SEQ ID NO: 17 and a VL region as set forth in SEQ ID NO: 18; e) comprising a VH region as set forth in SEQ ID NO: 27 and a VL region as set forth in SEQ ID NO: 28; or The monoclonal antibody of the present invention is f) binds to the same sBCMA epitope as the antibody in c) or competes for binding to sBCMA with the antibody in c); g) binds to the same sBCMA epitope as the antibody in d) or competes for binding to sBCMA with the antibody in d); or h) binds to the same sBCMA epitope as the antibody in e) or competes with the antibody in e) for binding to sBCMA.

[0092] It is envisaged that the monoclonal antibody of the invention (or "first monoclonal antibody") and / or the second monoclonal antibody as defined herein binds to sBCMA in a sample. According to one embodiment, the sample may be a biological sample. According to one embodiment, the sample is a human sample, such as a human biological sample. The biological sample may be a (human) serum sample, a plasma sample, a blood sample, a bone marrow sample or a tissue sample. The sample may also be a supernatant obtained from a cell culture of (human) bone marrow mononuclear cells or (human) peripheral blood mononuclear cells. The sample may be obtained from a subject (e.g. a human subject) suspected of having or having (diagnosed with) a disease associated with sBCMA or increased sBCMA or a subject undergoing treatment for a disease associated with sBCMA or increased sBCMA.

[0093] "Blood" is the bodily fluid of humans and other animals that delivers essential substances (e.g., nutrients and oxygen) to cells and carries metabolic waste products away from these same cells. In vertebrates, blood is composed of blood cells suspended in plasma. Blood plasma or "plasma" is the liquid component of blood in which several types of blood cells are suspended. Plasma is mostly water and contains dissolved proteins (e.g., serum albumin, globulins, fibrinogen, etc.), glucose, clotting factors, electrolytes, hormones, carbon dioxide, and oxygen. Blood serum or "serum" is plasma that does not contain clotting factors. Thus, serum contains all the plasma proteins that are not used in clotting. "Bone marrow" is a semi-solid tissue that can be found in the spongy or cancellous parts of bones. "Tissue" refers to a level of cellular organization between cells and complete organs. A tissue is a collection of similar cells and their extracellular matrix from the same origin that together perform a specific function. Tissues are then functionally grouped together to form organs.

[0094] Covalent modifications of the monoclonal antibodies (or antibody constructs) of the present invention are also included within the scope of the present invention, which are generally, but not necessarily, performed post-translationally. For example, some types of covalent modifications of antibodies are introduced into the molecule by reacting specific amino acid residues of the antibody with organic derivatizing agents that can react with selected side chains or N- or C-terminal residues. Derivatization with bifunctional agents is useful for crosslinking the antibodies of the present invention to water-insoluble support matrices or surfaces for use in various methods, particularly detection methods. Glutaminyl and asparaginyl residues are often deamidated to the corresponding glutamyl and aspartyl residues, respectively. Alternatively, these residues are deamidated under mildly acidic conditions. Either form of these residues is included within the scope of the present invention. Other modifications include: hydroxylation of proline and lysine, phosphorylation of the hydroxyl group of seryl or threonyl residues, methylation of the α-amino groups of lysine, arginine and histidine side chains (TECreighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, 1983, pp. 79-86), acetylation of the N-terminal amine and amidation of any C-terminal carboxyl group.

[0095] According to the present invention, the monoclonal antibody (or antibody construct), the "first" monoclonal antibody (or antibody construct) and / or the second monoclonal antibody (or antibody construct) are conjugated to a detectable label. In some embodiments, the covalent modification of the monoclonal antibody of the present invention comprises the addition of one or more labels (e.g., detectable labels). The antibody may be conjugated to a label or labeling group via a spacer arm of various lengths to reduce potential steric hindrance. A variety of protein labeling methods are known in the art and may be used in the practice of the present invention. The term "label" or "labeling group" refers to any detectable label. In general, labels are divided into various classes depending on the assay in which they are detected, examples of which include, but are not limited to, the following: a) an isotopic label, which may be a radioisotope or a heavy isotope, such as a radioisotope or a radionuclide (e.g., 3 H, 14 C. 15 N, 35 S, 89 Zr, 90 Y, 99 Tc, 111 In, 125 I, 131 I) b) Magnetic labels (e.g., magnetic particles) c) redox-active moieties d) optical dyes (including but not limited to chromophores, fluorophores and fluorophores), such as fluorescent groups (e.g., FITC, rhodamine, lanthanide fluorophores), chemiluminescent groups and fluorophores, which can be either "small molecule" fluorophores or proteinaceous fluorophores; e) Enzymes (e.g., horseradish peroxidase, β-galactosidase, luciferase, alkaline phosphatase) f) Biotinylation Group g) A predetermined polypeptide epitope recognized by a secondary reporter (eg, a leucine zipper pair sequence, a binding site for a secondary antibody, a metal binding domain, an epitope tag, etc.).

[0096] "Fluorescent label" refers to any molecule that can be detected by its inherent fluorescent properties. Suitable fluorescent labels include, but are not limited to, fluorescein, rhodamine, tetramethylrhodamine, eosin, erythrosine, coumarin, methylcoumarins, pyrene, malachite green, stilbene, Lucifer Yellow, Cascade BlueJ, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640, Cy 5, Cy 5.5, LC Red 705, Oregon Green, Alexa-Fluor dyes (Alexa Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa Fluor 680), Cascade Blue, Cascade Yellow, and R-Phycoerythrin (PE) (Molecular Probes, Eugene, OR), FITC, rhodamine and Texas Red (Pierce, Rockford, IL), Cy5, Cy5.5, Cy7 (Amersham Life Science, Pittsburgh, PA). Suitable optical dyes, such as fluorophores, are described in Molecular Probes Handbook by Richard P. Haugland.

[0097] Suitable proteinaceous fluorescent labels also include, but are not limited to, green fluorescent protein, e.g., GFP of Renilla, Ptilosarcus or Aequorea species (Chalfie et al., 1994, Science 263:802-805), EGFP (Clontech Laboratories, Inc., Genbank® Accession No. U55762), blue fluorescent protein (BFP, Quantum Biotechnologies, Inc. 1801 de Maisonneuve Blvd. West, 8th Floor, Montreal, Quebec, Canada H3H 1J9; Stauber, 1998, Biotechniques 24:462-471; Heim et al., 1996, Curr. Biol. 6:178-182), enhanced yellow fluorescent protein (EYFP, Clontech Laboratories, Inc.), luciferase (Ichiki et al., 1997, Biochem. 26:131-132), and the like. al., 1993, J. Immunol. 150:5408-5417), β-galactosidase (Nolan et al. al., 1988, Proc. Natl. Acad. Sci. USA 85:2603-2607) and Renilla (WO 92 / 15673; WO 95 / 07463; WO 98 / 14605; WO 98 / 26277; WO 99 / 49019; U.S. Pat. Nos. 5,292,658; 5,418,155; 5,683,888; 5,741,668; 5,777,079; 5,804,387; 5,874,304; 5,876,995; and 5,925,558).

[0098] The antibody / antibody construct of the present invention may also include additional domains, for example, that aid in the isolation of the molecule or that are relevant for adapting the pharmacokinetic profile of the molecule. The domains that aid in the isolation of the antibody / antibody construct may be selected from peptide motifs or secondarily introduced moieties that can be captured in an isolation method (e.g., an isolation column). Non-limiting examples of such additional domains include peptide motifs known as Myc tags, HAT tags, HA tags, TAP tags, GST tags, chitin-binding domains (CBD tags), maltose-binding protein (MBP tags), Flag tags, Strep tags and variants thereof (e.g., StrepII tags) and His tags. All of the antibody constructs disclosed herein that feature identified CDRs may include a His tag domain, commonly known as a repeat of consecutive His residues (e.g., five His residues or six His residues (hexahistidine)) in the amino acid sequence of the molecule. The His tag may, for example, be located at the N-terminus or C-terminus of the antibody construct. In one embodiment, the antibody construct of the present invention has a hexahistidine tag linked to the C-terminus by a peptide bond.

[0099] The present invention further provides a polynucleotide / nucleic acid molecule encoding the monoclonal antibody (or antibody construct) of the present invention. A nucleic acid molecule is a biopolymer composed of nucleotides. A polynucleotide is a biopolymer composed of 13 or more nucleotide monomers covalently linked in a chain. DNA (e.g., cDNA) and RNA (e.g., mRNA) are examples of polynucleotides / nucleic acid molecules with distinct biological functions. Nucleotides are organic molecules that serve as monomers or subunits of nucleic acid molecules such as DNA or RNA. A nucleic acid molecule or polynucleotide of the present invention can be double-stranded or single-stranded, linear or circular. It is envisaged that the nucleic acid molecule or polynucleotide is comprised in a vector. Furthermore, it is envisaged that such a vector is comprised in a host cell. The host cell is capable of expressing the monoclonal antibody (or antibody construct) after, for example, transformation or transfection with the vector or polynucleotide / nucleic acid molecule of the present invention. For this purpose, the polynucleotide or nucleic acid molecule is operably linked to a control sequence.

[0100] The genetic code is a set of rules by which information coded in genetic material (nucleic acids) is translated into proteins. Biological decoding in living cells is accomplished by reading mRNA three nucleotides at a time, with ribosomes using tRNA molecules to carry the amino acids, which link the amino acids in the order specified by the mRNA. The code defines how the sequence of these nucleotide triplets, called codons, specifies which amino acid is to be added next during protein synthesis. With some exceptions, a three-nucleotide codon in a nucleic acid sequence specifies a single amino acid. Because the vast majority of genes are coded with the exact same code, this particular code is often referred to as the canonical or standard genetic code.

[0101] Codon degeneracy is the redundancy of the genetic code, manifested as a multiplicity of three-base pair codon combinations that specify an amino acid. Degeneracy arises because of the abundance of codons compared to the number of codeable amino acids. Codons that code for one amino acid can differ in any of their three positions, but in most cases, this difference is in the second or third position. For example, the codons GAA and GAG both specify glutamic acid and exhibit redundancy, but neither specifies any other amino acid, and therefore exhibit no ambiguity. The genetic code of various organisms may be biased to use one of several codons that code for the same amino acid over others, i.e., one may be found more frequently than would be expected by chance. For example, leucine is specified by six distinct codons, some of which are rarely used. Codon usage tables are available that detail the genomic codon usage for most organisms. In recombinant genetic technology, this effect is often exploited by implementing a technique called codon optimization, where polynucleotides are designed using the codons preferred by the respective host cell (e.g., human, hamster derived, Escherichia coli or Saccharomyces cerevisiae cells) to increase, for example, protein expression. Thus, it is envisaged that the polynucleotides / nucleic acid molecules of the present disclosure are codon optimized. Nevertheless, polynucleotides / nucleic acid molecules encoding the monoclonal antibodies (or antibody constructs) of the present invention may be designed using any codon that encodes a desired amino acid.

[0102] According to one embodiment, the polynucleotide / nucleic acid molecule of the present invention encoding the monoclonal antibody (or antibody construct) of the present invention is in the form of one single molecule or in the form of two or more separate molecules. If the antibody construct of the present invention is a single chain antibody construct, the polynucleotide / nucleic acid molecule encoding such a construct is most likely also in the form of one single molecule. However, it is also envisaged that the different components of the monoclonal antibody (e.g. heavy and light chains) or antibody construct are located on separate polypeptide chains, in which case the polynucleotide / nucleic acid molecule is most likely in the form of two (or more) separate molecules.

[0103] The same applies to vectors comprising the polynucleotide / nucleic acid molecules of the present invention. When the antibody construct of the present invention is a single chain antibody construct, one vector may comprise the polynucleotide encoding the antibody construct at one single location (as one single open reading frame, ORF). One vector may also comprise two or more polynucleotide / nucleic acid molecules at separate locations (with individual ORFs), each of which encodes a different component of the monoclonal antibody of the present invention (e.g., heavy and light chains) or different components of the antibody construct. It is envisaged that the vector comprising the polynucleotide / nucleic acid molecule of the present invention may be in the form of one single vector or two or more separate vectors. In one embodiment and for the purpose of expressing a monoclonal antibody (or antibody construct) in a host cell, the host cell of the invention should contain the polynucleotide / nucleic acid molecule encoding the monoclonal antibody (or antibody construct) or a vector comprising such a polynucleotide / nucleic acid molecule in its entirety, meaning that all components of the monoclonal antibody (or antibody construct), whether encoded as one single molecule or encoded in separate molecules / locations, post-translationally associate and together form the biologically active monoclonal antibody (or antibody construct) of the invention.

[0104] The present invention also provides a vector comprising the polynucleotide / nucleic acid molecule of the present invention. A vector is usually a nucleic acid molecule used as a vehicle to transfer (foreign) genetic material into a cell for the purpose of replication and / or expression. The term "vector" includes, but is not limited to, plasmids, viruses, cosmids and artificial chromosomes. Some vectors are specifically designed for cloning (cloning vectors), others for protein expression (expression vectors). To amplify the insert, so-called transcription vectors are mainly used. DNA manipulations are usually performed on E. coli vectors, which contain the elements necessary for the maintenance of the DNA in E. coli. However, vectors may also have elements that allow the maintenance of this vector in another organism, such as yeast, plant or mammalian cells, which vectors are called shuttle vectors. The insertion of a vector into a target or host cell is usually called transformation for bacterial cells and transfection for eukaryotic cells, while the insertion of a viral vector is often called transduction.

[0105] Generally, engineered vectors contain an origin of replication, a multiple cloning site, and a selectable marker. The vector itself is generally a nucleotide sequence (generally a DNA sequence) that contains an insert (transgene) and a larger sequence that serves as the "backbone" of the vector. The genetic code determines the polypeptide sequence of a given coding region, but other genomic regions may influence when and where this polypeptide is produced. Thus, in addition to the transgene insert and backbone, modern vectors may contain additional features such as: promoters, genetic markers, antibiotic resistance, reporter genes, targeting sequences, protein purification tags. Vectors called expression vectors (expression constructs) are specifically intended for the expression of a transgene in a target cell and generally have regulatory sequences.

[0106] The term "control sequence" refers to a DNA sequence necessary for the expression of an operably linked coding sequence in a particular host organism. For example, control sequences suitable for prokaryotes include promoters, optional operator sequences, and ribosome binding sites. Eukaryotic cells are known to utilize promoters, polyadenylation signals, Kozak sequences, and enhancers.

[0107] A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA of a presequence or secretory leader is operably linked to DNA of a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence, or a ribosome binding site is operably linked to a coding sequence if it is positioned such that it promotes translation. Generally, "operably linked" means that the nucleotide sequences being linked are contiguous, and in the case of a secretory leader, contiguous and in reading phase. However, enhancers need not be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0108] "Transfection" is the process of deliberately introducing a nucleic acid molecule or polynucleotide (including a vector) into a target cell. The term is primarily used for non-viral methods in eukaryotic cells. Transduction is often used to describe the virus-mediated transfer of a nucleic acid molecule or polynucleotide. Transfection of animal cells typically involves opening a transient pore or "hole" in the cell membrane to allow the uptake of material. Transfection can be performed using biological particles (e.g., viral transfection, also referred to as viral transduction), chemical-based methods (e.g., using calcium phosphate, lipofection, Fugene, cationic polymers, nanoparticles) or physical treatments (e.g., electroporation, microinjection, gene gun, cell squeezing, magnetofection, hydrostatic pressure, impalefection, sonication, optical transfection, heat shock).

[0109] The term "transformation" is used to describe the non-viral transfer of nucleic acid molecules or polynucleotides (including vectors) into non-animal eukaryotic cells, such as bacteria and also plant cells. Transformation is thus the genetic alteration of bacteria or non-animal eukaryotic cells, which occurs by direct uptake through the cell membrane from the surroundings and subsequent incorporation of exogenous genetic material (nucleic acid molecules). Transformation can be performed by artificial means. For transformation to occur, cells or bacteria must be in a state of transformation competent, which can occur as a time-limited response to environmental conditions such as starvation and cell density, and can also be artificially induced.

[0110] Furthermore, the present invention provides a host cell transformed or transfected with a polynucleotide / nucleic acid molecule of the present invention or a vector of the present invention. As used herein, the term "host cell" or "recipient cell" is intended to include any individual cell or cell culture that can be or has been a recipient of a vector encoding a monoclonal antibody (or antibody construct) of the present invention, an exogenous nucleic acid molecule and / or a polynucleotide; and / or a recipient of the monoclonal antibody (or antibody construct) itself. Introduction of the respective substance into a cell is carried out by transformation, transfection and the like (see above). The term "host cell" is also intended to include the progeny or potential progeny of a single cell. Since certain modifications may occur in subsequent generations, either due to natural, accidental or deliberate mutations or due to environmental influences, such progeny may not in fact be completely identical (in morphology or genomic or total DNA complement) to the parent cell, but still be within the scope of the term as used herein. Suitable host cells include prokaryotic or eukaryotic cells, and further include, but are not limited to, bacteria (e.g., E. coli), yeast cells, fungal cells, plant cells, and animal cells (e.g., insect cells and mammalian cells, such as hamster cells, mouse cells, rat cells, macaque cells, or human cells).

[0111] In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for the monoclonal antibodies (or antibody constructs) of the invention. Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, many other genera, species and strains are commonly available and useful herein, including, for example: Schizosaccharomyces pombe, Kluyveromyces hosts, such as K. lactis, K. fragilis (ATCC 12424), K. bulgaricus (ATCC 16045), K. wickeramii (ATCC 24178), K. waltii (ATCC 56500), K. drosophilarum (ATCC 56661), K. spp. (ATCC 56662), K. spp. (ATCC 56663), K. spp. (ATCC 56664), K. spp. (ATCC 56665), K. spp. (ATCC 56666), K. spp. (ATCC 56667), K. spp. (ATCC 56668), K. spp. (ATCC 56669), K. spp. (ATCC 56669), K. spp. (ATCC 56669), K. spp. (ATCC 56661), K. spp. (ATCC 56662), K. spp. (ATCC 56663), K. spp. (ATCC 56664), K. spp. (ATCC 56666), K. spp. (ATCC 56667), K. spp. (ATCC 56668), K. spp. (ATCC 56669 ... 36906, K. thermotolerans and K. marxianus; Yarrowia (EP 402226); Pichia pastoris (EP 183070); Candida; Trichoderma reesia (EP 244234); Neurospora crassa; Schwanniomyces, for example Schwanniomyces occidentalis. occidentalis; and filamentous fungi such as Neurospora, Penicillium, Tolypocladium and Aspergillus hosts such as A. nidulans and A. niger.

[0112] Suitable host cells for the expression of glycosylated monoclonal antibodies (or antibody constructs) are derived from multicellular organisms. Examples of invertebrate cells include plant cells and insect cells. Many strains and variants of baculoviruses and corresponding permissive insect host cells from hosts (e.g., Spodoptera frugiperda (caterpillar), Aedes aegypti (mosquito), Aedes albopictus (mosquito), Drosophila melanogaster (fruit fly) and Bombyx mori) have been identified. Various virus strains for transfection (e.g., the L-1 variant of Autographa californica NPV and the Bm-5 strain of Bombyx mori NPV) are publicly available and such viruses may be used as viruses herein according to the invention, particularly for transfection of Spodoptera frugiperda cells.

[0113] Plant cell cultures of cotton, corn, potato, soybean, petunia, tomato, Arabidopsis and tobacco can also be used as hosts. Cloning and expression vectors useful for producing proteins in plant cell cultures are known to those skilled in the art. See, for example, Hiatt et al., Nature (1989) 342:76-78, Owen et al. (1992) Bio / Technology 10:790-794, Artsaenko et al. (1995) The Plant J 8:745-750 and Fecker et al. (1996) Plant Mol Biol 32:979-986.

[0114] However, most interest has been in vertebrate cells, and propagation of vertebrate cells in culture (cell culture) has become a routine procedure. Examples of useful mammalian host cell lines are: monkey kidney CV1 lines transformed with SV40 (e.g., COS-7, ATCC CRL 1651); human embryonic kidney lines (e.g., 293 cells or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (e.g., BHK, ATCC CCL 10); Chinese hamster ovary cells / -DHFR (e.g., CHO, Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216 (1980)); mouse Sertoli cells (e.g., TM4, Mather, Biol. Reprod. 23:243-251 (1980)); monkey kidney cells (e.g., CVI ATCC CCL 70); African green monkey kidney cells (e.g., VERO-76, ATCC CRL 1587); human cervical carcinoma cells (e.g., HELA, ATCC CCL 2); canine kidney cells (e.g., MDCK, ATCC CCL 34); buffalo rat liver cells (e.g., BRL 3A, ATCC CRL 1442); human lung cells (e.g., W138, ATCC CCL 75); human liver cells (e.g., Hep G2, 1413 8065); mouse mammary tumor (e.g., MMT 060562, ATCC CCL-51); TRI cells (Mather et al., Annals NY Acad. Sci. (1982) 383:44-68); MRC 5 cells; FS4 cells; and human hepatoma lines (e.g., Hep G2).

[0115] In a further embodiment, the invention provides a process for producing a monoclonal antibody (or antibody construct) of the invention, comprising culturing a host cell of the invention under conditions permissive for expression of the monoclonal antibody (or antibody construct) of the invention, and recovering the produced monoclonal antibody (or antibody construct) from the culture.

[0116] As used herein, the term "culturing" refers to the maintenance, differentiation, growth, proliferation and / or propagation of cells in vitro under suitable conditions in a medium. Cells are grown and maintained in a cell growth medium at an appropriate temperature and gas mixture. Culture conditions vary widely for different cell types. Typical growth conditions are a temperature of about 37°C, a CO2 concentration of about 5% and a humidity of about 95%. Growth medium recipes can vary, for example, in pH, concentration of carbon source (e.g., glucose), nature and concentration of growth factors and the presence of other nutrients (e.g., amino acids or vitamins). Growth factors used in supplemented media are often derived from serum of animal blood (e.g., fetal bovine serum (FBS), calf serum (FCS), horse serum and porcine serum). Cells can be grown either in suspension culture or as adherent cultures. Some cell lines have also been modified to be viable in suspension culture and can therefore grow to higher densities than would be possible in adherent conditions.

[0117] The term "expression" includes any steps involved in the production of the monoclonal antibody (or antibody construct) of the invention, including but not limited to: transcription, post-transcriptional modification, translation, folding, post-translational modification, targeting to a specific intracellular or extracellular location, and secretion. The term "recovery" refers to a series of processes intended to isolate the monoclonal antibody (or antibody construct) from a cell culture. In the "recovery" or "purification" process, protein and non-protein parts of the cell culture can be separated to finally separate the desired monoclonal antibody (or antibody construct) from all other polypeptides and proteins. Separation steps usually exploit differences in protein size, physicochemical properties, binding affinity, and biological activity. Preparative purification aims to generate relatively large amounts of purified protein for subsequent use, while analytical purification generates relatively small amounts of protein for various research or analytical purposes.

[0118] When using recombinant techniques, the monoclonal antibody (or antibody construct) may be produced intracellularly, in the periplasmic space, or directly secreted into the medium. If the monoclonal antibody (or antibody construct) is produced intracellularly, the first step is to remove particulate debris, either host cells or lysed fragments, for example by centrifugation or ultrafiltration. The monoclonal antibody (or antibody construct) of the present invention may be produced in bacteria, such as, for example, E. coli. After expression, the construct may be isolated from the bacterial cell paste in a soluble fraction and purified, for example, by affinity chromatography and / or size exclusion. Final purification may be carried out in the same manner as the purification process of a monoclonal antibody (or antibody construct) expressed in mammalian cells and secreted into the medium. Carter et al. (Biotechnology (NY) 1992 Feb;10(2):163-7) describes a procedure for isolating antibodies secreted into the periplasmic space of E. coli.

[0119] If the monoclonal antibody (or antibody construct) is secreted into the medium, supernatants from such expression systems are generally first concentrated using a commercially available protein concentration filter (eg, an ultrafiltration unit).

[0120] The monoclonal antibody (or antibody construct) of the invention prepared from the host cells may be recovered or purified using, for example, hydroxylapatite chromatography, gel electrophoresis, dialysis, and affinity chromatography. Depending on the monoclonal antibody (or antibody construct) to be recovered, other protein purification techniques may also be used, such as fractionation on an ion exchange column, mixed-mode ion exchange, HIC, ethanol precipitation, size exclusion chromatography, reversed-phase HPLC, chromatography on silica, chromatography on heparin sepharose, chromatography on anion or cation exchange resins (e.g., polyaspartic acid columns), immunoaffinity (e.g., protein A / G / L) chromatography, chromatofocusing, SDS-PAGE, ultracentrifugation, and ammonium sulfate precipitation. In any of the above steps, protease inhibitors may be included to inhibit proteolysis, and antibiotics may be included to prevent the growth of contaminants.

[0121] The present invention further provides a composition or formulation comprising the monoclonal antibody (or antibody construct) of the present invention or comprising the monoclonal antibody (or antibody construct) produced by the process of the present invention. The composition is preferably a diagnostic composition. As used herein, the term "diagnostic composition" relates to a composition suitable for use in a diagnostic kit or detection system. One possible diagnostic composition of the present invention preferably comprises one or more of the monoclonal antibodies (or antibody constructs) of the present invention in an amount useful for the detection of sBCMA in a sample. The diagnostic composition may further comprise a suitable formulation of one or more carriers, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers, preservatives and / or adjuvants. Diagnostic compositions of the present invention include, but are not limited to, liquid compositions, frozen compositions and lyophilized compositions.

[0122] The composition may include a carrier, such as a diagnostically acceptable carrier. In general, as used herein, "diagnostically acceptable carrier" refers to any aqueous and non-aqueous solution, sterile solution, solvent, buffer (e.g., phosphate buffered saline (PBS) solution), water, suspension, emulsion (e.g., oil / water emulsion), various types of wetting agents, liposomes, dispersion media, and coatings that are suitable for diagnostic use. The use of such media and agents in diagnostic compositions is known in the art, and compositions containing such carriers may be formulated by known conventional methods.

[0123] In certain embodiments, diagnostic compositions are provided that comprise an antibody (or antibody construct) of the invention and one or more additional excipients, such as those exemplarily described in this section and elsewhere herein. Excipients may be used in the present invention for a variety of purposes, such as adjusting the physical, chemical or biological properties of the formulation (e.g., adjusting viscosity) and / or may be used in the processes of the invention to improve efficacy and / or stabilize such formulations and processes against degradation and deterioration due to, for example, manufacturing, shipping, storage, preparation prior to use, administration and subsequent stresses. Excipients should generally be used at their lowest effective concentration.

[0124] In certain embodiments, diagnostic compositions may include formulation materials for the purpose of modifying, maintaining or preserving certain characteristics of the composition, such as pH, osmolality, viscosity, clarity, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption or permeation (see Remington's Pharmaceutical Sciences, 18th Edition, 1990, Mack Publishing Company). In such embodiments, suitable formulation materials may include, but are not limited to: ·amino acid Antimicrobial agents such as antibacterial and antifungal agents Antioxidants Buffers, buffer systems and buffering agents used to maintain the composition at or slightly below physiological pH, typically within a pH range of about 5 to about 8 or 9 Non-aqueous solvents, vegetable oils and injectable organic esters Aqueous carriers such as water, alcoholic / aqueous solutions, emulsions or suspensions, e.g. saline and buffered media Biodegradable polymers such as polyester · Bulking agent Chelating agents ·Isotonicity and absorption retarding agents Complexing agents Fillers ·carbohydrates Preferably, (low molecular weight) proteins, polypeptides or proteinaceous carriers of human origin Colouring and flavouring agents Sulfur-containing reducing agent Diluents ·emulsifier Hydrophilic polymers Salt-forming counter ions Preservatives Metal complexes Solvents and co-solvents ·Sugars and sugar alcohols Suspension agents Surfactants or wetting agents Stabilizer ·Isotonicity enhancer Parenteral delivery vehicles Intravenous delivery vehicles.

[0125] It is common knowledge that various components of a diagnostic composition may have different effects, for example, amino acids may act as buffers, stabilizers and / or antioxidants; mannitol may act as a bulking agent and / or tonicity enhancer; sodium chloride may act as a delivery vehicle and / or tonicity enhancer.

[0126] According to a further aspect, the present invention provides a detection system comprising: a) a first monoclonal antibody (or antibody construct) that binds to sBCMA; and b) a second monoclonal antibody (or antibody construct) that binds to sBCMA; and wherein binding of a first monoclonal antibody (or antibody construct) to sBCMA occurs in the presence of a second monoclonal antibody (or antibody construct) that binds to sBCMA.

[0127] The present invention provides a detection system comprising: a) a first monoclonal antibody (or antibody construct) that binds to sBCMA; and b) a second monoclonal antibody (or antibody construct) that binds to sBCMA; and wherein binding of the second monoclonal antibody (or antibody construct) to sBCMA occurs in the presence of the first monoclonal antibody (or antibody construct) that binds to sBCMA.

[0128] The present invention provides a detection system comprising: a) a first monoclonal antibody (or antibody construct) that binds to sBCMA; and b) a second monoclonal antibody (or antibody construct) that binds to sBCMA; and wherein binding of a first monoclonal antibody (or antibody construct) to sBCMA occurs in the presence of a second monoclonal antibody (or antibody construct) that binds to sBCMA, and binding of the second monoclonal antibody (or antibody construct) to sBCMA occurs in the presence of the first monoclonal antibody (or antibody construct) that binds to sBCMA.

[0129] A "detection system" is a kit or tool (or diagnostic kit / tool) that contains reagents for carrying out an analytical assay. In the context of the present invention, the assay detects and / or quantifies the presence of sBCMA in a sample (usually a liquid sample). The detection system comprises a pair of antibodies (a first monoclonal antibody and a second monoclonal antibody) that bind to sBCMA. Typically, the detection system involves the use of a solid support (e.g., a microtiter plate or membrane) that serves as a surface for immobilizing either the antigen to be detected (e.g., in the case of a "direct ELISA") or a (monoclonal) antibody that binds to sBCMA (the "capture antibody") or a "second antibody" (e.g., an anti-Fc antibody) that binds to the antibody that binds to sBCMA (the capture antibody). Generally, this immobilization occurs non-specifically (by adsorption to the surface) or specifically (by capture by an antibody, such as a second antibody). The detection system may further comprise a (monoclonal) detection antibody that binds to sBCMA (optionally conjugated to an enzyme, detectable label or reporter group) and an optional second antibody (e.g. an anti-Fc antibody) that binds to the detection antibody and is conjugated to an enzyme, detectable label or reporter group. In this case, the capture antibody may be a "first monoclonal antibody (or antibody construct) that binds to sBCMA" and the detection antibody may be a "second monoclonal antibody (or antibody construct) that binds to sBCMA" or vice versa. In other words, the first or second monoclonal antibody or antibody construct of the invention may be conjugated to an enzyme, detectable label or reporter group.

[0130] A very well known detection system is the ELISA assay, which may be used for the purposes of the present invention. A "sandwich" ELISA is used to detect a sample antigen (herein sBCMA) or to quantify an unknown amount of this antigen. This step may include: preparing a surface to which a known amount of a so-called "capture antibody" is bound. This binding may occur directly by adsorption of the capture antibody to the surface, or through a second antibody (e.g. an anti-Fc antibody) that is adsorbed to the surface and binds to the capture antibody. Any non-specific binding sites on the surface are blocked. An antigen-containing sample is applied to the surface, and the antigen is captured (bound) by the antibody. The plate is washed and unbound antigen is removed. A "detection antibody" is added and allowed to bind to the antigen. This detection antibody may be conjugated (e.g. covalently linked) to an enzyme, detectable label or reporter group. Otherwise, a second antibody is applied that is conjugated to an enzyme, detectable label or reporter group and that binds to the detection antibody (e.g. the Fc region of the detection antibody). The plate is washed and any unbound antibody is removed. A chemical substrate is added that is converted (e.g., by an enzyme) into a detectable form (e.g., a light (e.g., color or fluorescence) or electrochemical signal). The absorbance or fluorescence or electrochemical signal (e.g., current) of the plate well or surface is measured to determine the presence and / or amount of antigen. Commonly used enzymatic markers include: - OPD (o-phenylenediamine dihydrochloride) produces an amber color and detects horseradish peroxidase (HRP), which is often used as a conjugated protein. - TMB (3,3',5,5'-tetramethylbenzidine) turns blue when it detects HRP and turns yellow when it detects sulfuric acid or phosphoric acid. - ABTS (2,2'-azinobis[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) turns green when detected by HRP - PNPP (p-nitrophenyl phosphate disodium salt) turns yellow when alkaline phosphatase is detected.

[0131] Traditional ELISAs typically include a chromogenic reporter and a substrate that can be observed to change color to indicate the presence of the antigen. Newer ELISA-like technologies use fluorescent, electrochemiluminescent, and quantitative PCR reporters to generate quantifiable signals. These new reporters may have various advantages, such as higher sensitivity and multiplexing. In technical terms, these assays are not strictly "ELISAs" because they are not "enzyme-linked" but instead bind to some non-enzymatic reporter. However, given that the general principles of these assays are largely similar, these assays are often classified in the same category as ELISAs.

[0132] The detection system may be used in a qualitative format or it may be used in a quantitative format. A qualitative result provides a simple positive or negative result (yes or no) for the sample. The cutoff between positive and negative may be statistical. Two to three times the standard deviation (the error inherent in the test) is often used to distinguish positive from negative samples. In a quantitative format, the optical density (OD) or electrochemical signal of the sample is compared to a standard curve, which is typically a serial dilution of a solution of known concentration of the target molecule (sBCMA).

[0133] The definitions and specifications of the monoclonal antibody of the present invention and the second monoclonal antibody provided herein above apply equally to the first and second monoclonal antibodies comprised within the detection system of the present invention. For example, it is envisaged that sBCMA has the amino acid sequence shown in SEQ ID NO: 34. It is also envisaged that the binding of the first monoclonal antibody to sBCMA and the binding of the second monoclonal antibody to sBCMA occurs in the presence of a third antibody or antibody construct that binds to sBCMA. This third antibody or antibody construct may be a therapeutic anti-BCMA antibody or antibody construct (e.g. an antibody drug conjugate (ADC) or a CD3 x BCMA bispecific antibody). This third antibody or antibody construct may be present in the sample (e.g. a biological sample) to be analysed using the present detection system. For further details of the third antibody / antibody construct that binds to sBCMA, see herein above. It is further contemplated that the first monoclonal antibody (or antibody construct) of the present detection system comprises (a) a rabbit VH region, (b) a rabbit VL region, or (c) a rabbit VH region and a rabbit VL region. Similarly, the second monoclonal antibody (or antibody construct) of the present detection system may comprise (a) a rabbit VH region, (b) a rabbit VL region, or (c) a rabbit VH region and a rabbit VL region. Furthermore, the entire first monoclonal antibody and / or the entire second monoclonal antibody of the present detection system may be a rabbit antibody. The first monoclonal antibody and / or the second monoclonal antibody of the present detection system may have a molecular weight of about ≦10 -7 M, ≦10 -8 M, ≦10 -9 M or ≦10 -10It is also envisioned that the first monoclonal antibody of the detection system and / or the second monoclonal antibody of the detection system have an affinity (KD) for sBCMA of 100-200 M. It is also envisioned that the first monoclonal antibody of the detection system and / or the second monoclonal antibody of the detection system are IgG, IgD, IgE, IgM or IgA antibodies. According to one embodiment, the first and / or second monoclonal antibody are IgG antibodies, such as IgG1, IgG2, IgG3 or IgG4 antibodies. The isotype and subclass of the antibody may be rabbit (e.g., rabbit IgG, rabbit IgG1, etc.).

[0134] The present invention relates to a method for detecting a first monoclonal antibody (or an antibody construct) of the present detection system, a) comprising a VH region comprising VH-CDR1 shown in SEQ ID NO: 1, VH-CDR2 shown in SEQ ID NO: 2, and VH-CDR3 shown in SEQ ID NO: 3, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 4, VL-CDR2 shown in SEQ ID NO: 5, and VL-CDR3 shown in SEQ ID NO: 6; b) a VH region comprising VH-CDR1 shown in SEQ ID NO: 11, VH-CDR2 shown in SEQ ID NO: 12, and VH-CDR3 shown in SEQ ID NO: 13, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 14, VL-CDR2 shown in SEQ ID NO: 15, and VL-CDR3 shown in SEQ ID NO: 16; c) binds to the same sBCMA epitope as the antibody in a) or competes for binding to sBCMA with the antibody in a); or d) binds to the same sBCMA epitope as the antibody of b) or competes for binding to sBCMA with the antibody of b); and / or The second monoclonal antibody (or antibody construct) of the detection system is e) a VH region comprising VH-CDR1 as set forth in SEQ ID NO: 21, VH-CDR2 as set forth in SEQ ID NO: 22, and VH-CDR3 as set forth in SEQ ID NO: 23, and a VL region comprising VL-CDR1 as set forth in SEQ ID NO: 24, VL-CDR2 as set forth in SEQ ID NO: 25, and VL-CDR3 as set forth in SEQ ID NO: 26; or f) Binds to the same sBCMA epitope as the antibody in e) or competes with the antibody in e) for binding to sBCMA. Also provided.

[0135] The present invention relates to a method for detecting a first monoclonal antibody (or an antibody construct) of the present detection system, a) comprises a VH region as set forth in SEQ ID NO: 7 or 17; b) comprises a VL region as set forth in SEQ ID NO: 8 or 18; c) comprising a VH region as set forth in SEQ ID NO: 7 and a VL region as set forth in SEQ ID NO: 8; d) comprising a VH region as set forth in SEQ ID NO: 17 and a VL region as set forth in SEQ ID NO: 18; e) binds to the same sBCMA epitope as the antibody in c) or competes for binding to sBCMA with the antibody in c); or f) binds to the same sBCMA epitope as the antibody of d) or competes for binding to sBCMA with the antibody of d); and / or The second monoclonal antibody (or antibody construct) of the detection system is g) comprises a VH region as set forth in SEQ ID NO: 27; h) comprises a VL region as set forth in SEQ ID NO: 28; i) comprising a VH region as set forth in SEQ ID NO: 27 and a VL region as set forth in SEQ ID NO: 28; or j) binds to the same sBCMA epitope as the antibody in i) or competes with the antibody in i) for binding to sBCMA. Also provided.

[0136] Regarding this detection system, a) a first monoclonal antibody (or antibody construct) is used as a capture antibody and a second monoclonal antibody (or antibody construct) is used as a detection antibody, or b) It is envisaged that a first monoclonal antibody (or antibody construct) is used as a detection antibody and a second monoclonal antibody (or antibody construct) is used as a capture antibody.

[0137] In a further aspect, the present invention relates to the use of a monoclonal antibody (or antibody construct) of the invention or a detection system of the invention, - detecting sBCMA in a sample; - quantitating sBCMA in a sample; - diagnosing a disease associated with sBCMA or increased sBCMA; - stratify patients diagnosed with sBCMA or diseases associated with increased sBCMA; - monitoring the progression of a disease associated with sBCMA or increased sBCMA; or - monitoring response to treatment of sBCMA or diseases associated with increased sBCMA The present invention also provides the use of a monoclonal antibody (or antibody construct) of the invention or a detection system of the invention for:

[0138] In one embodiment, the sample is a biological sample, for example a human biological sample. The sample (biological sample / human biological sample) can be a serum sample, plasma sample, blood sample, bone marrow sample or tissue sample. The sample can also be a supernatant obtained from a cell culture of bone marrow mononuclear cells or peripheral blood mononuclear cells. The sample can be obtained from a subject (e.g., a human subject) suspected of having or having (diagnosed with) a disease associated with sBCMA or increased sBCMA, or a subject undergoing treatment for a disease associated with sBCMA or increased sBCMA.

[0139] A disease is a specific abnormal condition that adversely affects some or all of the structure or function of an organism, such as a human, and does not result from any trauma. A disease is often interpreted as a "pathology" or "disorder" with specific signs and symptoms. The disease according to the present invention is associated with sBCMA or increased sBCMA. The sBCMA may be detected and / or quantified, for example, in bone marrow, blood, serum or plasma of a human subject, or in supernatants obtained from cell cultures of bone marrow mononuclear cells or peripheral blood mononuclear cells of a human subject. The term "increased" is used in comparison to healthy subjects (i.e. subjects without such disease). According to one embodiment, the disease associated with sBCMA or increased sBCMA is a "BCMA-positive neoplasm."

[0140] A "neoplasm" is an abnormal growth of tissue, usually, but not necessarily, forming a mass. When it also forms a mass, the neoplasm is commonly referred to as a "tumor." In brain tumors, the uncontrolled division of cells means that the neoplastic mass increases in size, and in a closed space such as the intracranial cavity, this quickly becomes problematic as the mass invades the brain space and displaces the brain, leading to compression of brain tissue and increased intracranial pressure and destruction of the parenchyma. According to the present invention, "neoplasm" or "tumor" also refers to a condition that would benefit from treatment with a therapy directed against BCMA (particularly BCMA expressed on the cell surface) (e.g., BCMA-specific antibodies, e.g. naked antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, e.g., those directed against BCMA and CD3, and cell therapies such as chimeric antigen receptor T cells (CAR-T)), including, but not limited to, AMG 420, AMG 701, GSK 916, JNJ-64007957 (JNJ-7957), PF-06863135 (PF-3135), CC-93269, REGN5458, HPN217, TNB-383B, P-BCMA-101, JNJ-68284528, JCARH125, and bb2121. The conditions include chronic and acute disorders or diseases, including pathological conditions that afflict a mammal with the condition of interest (neoplasia or tumor).

[0141] Neoplasms or tumors can be benign, potentially malignant (precancerous), or malignant (cancerous). Malignant neoplasms / tumors are commonly referred to as cancers. They usually invade and destroy surrounding tissues, and may also form metastases, i.e., spread to other parts, tissues, or organs of the body. A "primary tumor" is a tumor that grows at an anatomical site where tumor progression begins and progresses to result in a cancerous mass. For example, a brain tumor occurs when abnormal cells form in the brain. Most cancers develop at their primary site, but then form metastases or spread to other parts (e.g., tissues and organs) of the body. These additional tumors are secondary tumors. Most cancers continue to be named after their primary site even after they have spread to other parts of the body.

[0142] Lymphomas and leukemias are hematopoietic or lymphoid neoplasms. For the purposes of this invention, lymphomas and leukemias are also encompassed by the terms "tumor," "cancer," or "neoplasm." Lymphomas are a group of blood cancers that arise from lymphocytes (a type of white blood cell). Leukemias are a group of cancers that usually begin in the bone marrow and result in large numbers of abnormal white blood cells. These white blood cells are not fully developed and are called blasts or leukemia cells. Lymphomas and leukemias are part of a broader group of tumors of the hematopoietic and lymphatic tissues.

[0143] For purposes of the present invention, the terms "neoplasm," "tumor," and "cancer" may be used interchangeably and include both primary tumors / cancers and secondary tumors / cancers (or "metastases") as well as mass-forming neoplasms (tumors) and lymphoid neoplasms (e.g., lymphomas and leukemias), including MRD.

[0144] The term "minimal residual disease" (MRD) refers to evidence of the presence of a small number of residual cancer cells remaining in a patient after cancer treatment, for example when the patient is in remission (the patient has no symptoms or signs of the disease). The very small number of residual cancer cells cannot usually be detected by conventional means because standard tests used to evaluate or detect cancer are insufficiently sensitive to detect MRD. Recently, highly sensitive molecular biological MRD tests such as flow cytometry, PCR and next generation sequencing have become available. These tests can measure minimal levels of cancer cells in tissue samples, sometimes as little as one cancer cell in a million normal cells. In the context of the present invention, the terms "prevention," "treatment," or "amelioration" of a neoplasm are also envisioned to encompass "prevention, treatment, or amelioration of MRD," regardless of whether MRD has been detected or not.

[0145] BCMA positive neoplasms are assumed to be B cell or plasma cell neoplasms. B cells, also known as B lymphocytes, are a type of white blood cell of the lymphocyte subtype. B cells function in the humoral immune component of the adaptive immune system by secreting antibodies. In addition, B cells present antigens (also classified as professional antigen presenting cells) and secrete cytokines. In mammals, B cells mature in the bone marrow, which is located in the center of most bones. B cells differ from the other two classes of lymphocytes (T cells and natural killer (NK) cells) in that they express a B cell receptor (BCR) on the cell membrane. The BCR allows B cells to bind to specific antigens and initiate an antibody response against them. Plasma cells, also called plasma B cells, plasma cells, or effector B cells, are white blood cells that secrete large amounts of antibodies. Plasma cells are normally transported by the plasma and lymphatic system. Plasma cells originate from the bone marrow. B cells differentiate into plasma cells that produce antibody molecules that are closely modeled on the receptors of precursor B cells. Once released into the blood and lymph, these antibody molecules bind to target antigens and begin to neutralize or destroy them.

[0146] A "disease associated with sBCMA or increased sBCMA", "BCMA positive neoplasm" or "(BCMA positive) B cell or plasma cell neoplasm" may be selected from the group including, but not limited to, multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma (extramedullary plasmacytoma, extramedullary multiple myeloma), plasmacytoma, plasma cell leukemia, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), smoldering myeloma (smoldering multiple myeloma), chronic lymphocytic leukemia (CLL), primary CNS lymphoma (PCNSL) and B cell non-Hodgkin's lymphoma (B-NHL). The multiple myeloma may be selected from the group consisting of or including relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary multiple myeloma and smoldering multiple myeloma.

[0147] "Diagnosis" or "medical diagnosis" is the process of determining which disorder or condition explains the symptoms and signs of a subject. Usually, during this process, one or more diagnostic procedures, such as diagnostic tests or medical tests, are performed. In medicine, the term "monitoring" refers to the observation of a disease, condition, or one or several medical parameters over time. Monitoring can be performed by using medical monitors and / or by repeatedly performing medical tests to continuously measure a particular parameter. Diagnostic tests or medical tests are medical procedures performed to detect, diagnose or monitor a disease, disease course, susceptibility, and / or to determine a course of treatment. Diagnostic tests or medical tests are related to clinical chemistry and molecular diagnostics, and the procedures are typically performed in medical laboratories.

[0148] Medical therapy or treatment is an effort to cure or ameliorate a disease. In the medical field, common treatments include drug therapy. Drugs (also called medicines, pharmaceuticals or drugs) are used to diagnose, cure, treat or prevent a disease. The term "treatment" therefore refers to both therapeutic treatment and prophylactic or preventative measures. In the context of the present invention, treatment includes the application or administration of an anti-BCMA antibody or antibody construct to the body, isolated tissue or cells of a patient or subject in need having a disease as described herein, a symptom of such a disease or a predisposition to such a disease, with the aim of curing, curing, alleviating, mitigating, altering, treating, ameliorating, reversing or affecting the disease, the symptoms of the disease or the predisposition to a disease.

[0149] In a further aspect, the present invention provides a method for detecting and / or quantitating sBCMA in a sample, comprising the steps of: (a) using a monoclonal antibody (or antibody construct) of the invention or using a detection system of the invention to determine the content of sBCMA in a sample; (b) the content of sBCMA determined in step (a), (i) a predefined value for sBCMA content; (ii) the content of sBCMA determined in a control sample; or (iii) the content of sBCMA determined in a sample obtained from the same source or subject at an earlier time point; A process of comparing with Also provided is a method comprising:

[0150] For the purposes of the present invention, the term "content" (of sBCMA) may be used interchangeably with the terms "level", "amount" or "concentration" (of sBCMA). A "predefined value for sBCMA content" may be a "cut-off value" that has been determined in advance. This value may indicate, for example, that a particular sBCMA content in a sample is indicative of sBCMA or a disease associated with increased sBCMA, or indicative of a BCMA-positive neoplasm. For example, if the sBCMA content in a sample is determined to be greater than three standard deviations above the pre-determined cut-off value, the subject from which the sample was taken is considered positive for multiple myeloma (or other disease as described herein). A "control sample" is usually obtained from a source of the same nature as the sample to be analyzed (e.g., a serum sample). A control sample may be a sample that represents a "normal" sBCMA content (e.g., representing a healthy subject) (a "negative control sample"), or a sample that represents an "abnormally increased" sBCMA content (e.g., representing a subject with a disease as defined herein) (a "positive control sample").

[0151] In a further aspect, the present invention provides a method for diagnosing sBCMA or a disease associated with increased sBCMA, comprising the steps of: (a) using a monoclonal antibody (or antibody construct) of the invention or using a detection system of the invention to determine the content of sBCMA in a sample; (b) the content of sBCMA determined in step (a), (i) a predefined cut-off value for sBCMA content that indicates the absence of such disease, or (ii) the content of sBCMA determined in a control sample representative of the absence of such disease; A process of comparing with wherein a higher content of sBCMA determined in step (a) compared to a pre-defined cut-off value in (i) or the content of sBCMA determined in a control sample in (ii) indicates the presence of sBCMA or a disease associated with increased sBCMA.

[0152] In a further aspect, the present invention provides a method of monitoring the progression of a disease associated with sBCMA or increased sBCMA or monitoring the response to treatment of a disease associated with sBCMA or increased sBCMA, comprising: (a) using a monoclonal antibody (or antibody construct) of the invention or using a detection system of the invention to determine the content of sBCMA at a first time point in a biological sample obtained from a subject diagnosed with such a disease; (b) using a monoclonal antibody (or antibody construct) of the invention or using a detection system of the invention to determine the content of sBCMA in a biological sample obtained from the subject at a second (later) time point or after treatment; (c) comparing the content of sBCMA determined in step (a) with the content of sBCMA determined in step (b); wherein a higher content of sBCMA determined in step (a) compared to the content of sBCMA determined in step (b) indicates that the disease is progressing, and / or a lower content of sBCMA determined in step (a) compared to the content of sBCMA determined in step (b) indicates that the disease is going into remission or that the disease is responding to treatment.

[0153] With respect to the above method, it is envisaged that the "sample" is a biological sample, for example a human biological sample. This sample may be a (human) serum sample, a plasma sample, a blood sample, a bone marrow sample, a tissue sample or a supernatant obtained from a cell culture of (human) bone marrow mononuclear cells or (human) peripheral blood mononuclear cells. This "sample" may also be obtained from a human subject, as defined herein above, preferably a human subject suspected or having (diagnosed) a disease associated with sBCMA or increased sBCMA or a subject undergoing treatment for a disease associated with sBCMA or increased sBCMA.

[0154] With respect to the above method, it is envisaged that the "disease associated with sBCMA or increased sBCMA" may be a BCMA positive neoplasm. The disease or BCMA positive neoplasm may be selected from the group consisting of multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma (extramedullary plasmacytoma, extramedullary multiple myeloma), plasmacytoma, plasma cell leukemia, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), smoldering myeloma (smoldering multiple myeloma), chronic lymphocytic leukemia (CLL), primary CNS lymphoma (PCNSL) and B-cell non-Hodgkin's lymphoma (B-NHL).

[0155] The present invention relates to the following items. Item 1. A monoclonal antibody that binds to soluble BCMA (sBCMA), where binding of the antibody to sBCMA occurs in the presence of a second monoclonal antibody that binds sBCMA. Item 2. The monoclonal antibody described in Item 1, wherein sBCMA has the amino acid sequence set forth in SEQ ID NO: 34. Item 3. The monoclonal antibody according to item 1 or 2, wherein binding of the monoclonal antibody to sBCMA occurs in the presence of a third antibody or antibody construct that binds to sBCMA. Item 4. The third monoclonal antibody or antibody construct binds to epitope cluster 3 of BCMA, preferably binds to epitope cluster 3 of human BCMA, and preferably has the amino acid sequence as set forth in SEQ ID NO: 35. Item 5. The monoclonal antibody according to any one of Items 1 to 4, which comprises a rabbit VH region and / or a rabbit VL region. Item 6. About ≦10 -7 M, ≦10 -8 M, ≦10 -9 M or ≦10 -10 6. The monoclonal antibody according to any one of items 1 to 5, having an affinity (KD) for sBCMA of M. Item 7. The monoclonal antibody according to item 6, wherein the affinity is determined by a Biacore assay. Item 8.a) A VH region comprising VH-CDR1 shown in SEQ ID NO: 1, VH-CDR2 shown in SEQ ID NO: 2, and VH-CDR3 shown in SEQ ID NO: 3, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 4, VL-CDR2 shown in SEQ ID NO: 5, and VL-CDR3 shown in SEQ ID NO: 6; b) a VH region comprising VH-CDR1 shown in SEQ ID NO: 11, VH-CDR2 shown in SEQ ID NO: 12, and VH-CDR3 shown in SEQ ID NO: 13, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 14, VL-CDR2 shown in SEQ ID NO: 15, and VL-CDR3 shown in SEQ ID NO: 16; c) a VH region comprising VH-CDR1 shown in SEQ ID NO: 21, VH-CDR2 shown in SEQ ID NO: 22, and VH-CDR3 shown in SEQ ID NO: 23, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 24, VL-CDR2 shown in SEQ ID NO: 25, and VL-CDR3 shown in SEQ ID NO: 26; d) binds to the same sBCMA epitope as the antibody in a) or competes for binding to sBCMA with the antibody in a); e) binds to the same sBCMA epitope as the antibody in b) or competes for binding to sBCMA with the antibody in b); or f) A monoclonal antibody according to any one of items 1 to 7, which binds to the same sBCMA epitope as the antibody of c) or competes with the antibody of c) for binding to sBCMA. Item 9.a) A VH region comprising an amino acid sequence that is at least 60%, 65% or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98% or 99% homologous to SEQ ID NO: 7, and a VH region comprising an amino acid sequence that is at least 60%, 65% or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90% , 91%, 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98% or 99% identical to said VH-CDR1, and optionally comprising a VH-CDR1 as set forth in SEQ ID NO:1, a VH-CDR2 as set forth in SEQ ID NO:2 and a VH-CDR3 as set forth in SEQ ID NO:3, and optionally comprising a VL-CDR1 as set forth in SEQ ID NO:4, a VL-CDR2 as set forth in SEQ ID NO:5 and a VL-CDR3 as set forth in SEQ ID NO:6; b) a VH region comprising an amino acid sequence that is at least 60%, 65% or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98% or 99% homologous to SEQ ID NO: 17; and 95%, 96%, 97%, 98% or 99% identical to said VH-CDR1 in SEQ ID NO:11, said VH-CDR2 in SEQ ID NO:12 and said VH-CDR3 in SEQ ID NO:13, and a VL-CDR1 in SEQ ID NO:14, said VL-CDR2 in SEQ ID NO:15 and said VL-CDR3 in SEQ ID NO:16; or c) a VH region comprising an amino acid sequence that is at least 60%, 65% or 70%, preferably at least 75% or 80%, more preferably at least 85%, 90%, 91%, 92%, 93%, 94%, and most preferably 95%, 96%, 97%, 98% or 99% homologous to SEQ ID NO: 27; and 9. The monoclonal antibody of item 8, comprising a VH region comprising an amino acid sequence that is 4%, most preferably 95%, 96%, 97%, 98% or 99% identical to said VH region, and optionally comprising a VH-CDR1 as set forth in SEQ ID NO: 21, a VH-CDR2 as set forth in SEQ ID NO: 22 and a VH-CDR3 as set forth in SEQ ID NO: 23, and a VL region comprising a VL-CDR1 as set forth in SEQ ID NO: 24, a VL-CDR2 as set forth in SEQ ID NO: 25 and a VL-CDR3 as set forth in SEQ ID NO: 26. Item 10.a) comprises a VH region set forth in any one of SEQ ID NOs: 7, 17, or 27; b) comprises a VL region as set forth in any one of SEQ ID NOs: 8, 18, or 28; c) comprising a VH region as set forth in SEQ ID NO: 7 and a VL region as set forth in SEQ ID NO: 8; d) comprising a VH region as set forth in SEQ ID NO: 17 and a VL region as set forth in SEQ ID NO: 18; e) comprising a VH region as set forth in SEQ ID NO:27 and a VL region as set forth in SEQ ID NO:28; f) binds to the same sBCMA epitope as the antibody in c) or competes for binding to sBCMA with the antibody in c); g) binds to the same sBCMA epitope as the antibody in d) or competes for binding to sBCMA with the antibody in d); or h) A monoclonal antibody according to item 8, which binds to the same sBCMA epitope as the antibody of e) or competes with the antibody of e) for binding to sBCMA. Item 11. The monoclonal antibody according to any one of items 7 to 10, wherein binding to the sBCMA epitope is determined via epitope mapping with chimeric or mutated BCMA molecules, site-directed mutagenesis (e.g. alanine scanning), high throughput shotgun mutagenesis epitope mapping, crosslinking coupled mass spectrometry, X-ray co-crystallography, cryo-electron microscopy and hydrogen-deuterium exchange. Item 12. The monoclonal antibody according to any one of items 7 to 10, wherein the competition for binding to sBCMA is determined in a competitive ELISA assay, an Octet competitive assay (as described in Example 2 herein) or a competitive assay using avidin-conjugated microparticles. Item 13. The monoclonal antibody according to any one of items 7 to 10 or item 12, wherein competition for binding to sBCMA is defined as a competition occurring between the two tested antibodies of at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90%. Item 14. The monoclonal antibody according to any one of items 1 to 13, which is an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody or an IgA antibody, preferably an IgG antibody, for example an IgG1 antibody, an IgG2 antibody, an IgG3 antibody or an IgG4 antibody. Item 15. The monoclonal antibody according to any one of items 1 to 14, wherein the monoclonal antibody and / or the second monoclonal antibody binds to sBCMA in a biological sample, preferably a human biological sample, such as a (human) serum sample, a (human) plasma sample, a (human) blood sample, a (human) bone marrow sample, a (human) tissue sample or a supernatant obtained from a cell culture of (human) bone marrow mononuclear cells or (human) peripheral blood mononuclear cells. Item 16. A polynucleotide encoding the monoclonal antibody according to any one of Items 1 to 15. Item 17. A vector comprising the polynucleotide according to Item 16. Item 18. A host cell transformed or transfected with the polynucleotide according to item 16 or the vector according to item 17. Item 19. A process for producing the monoclonal antibody according to any one of items 1 to 15, comprising culturing the host cell according to item 18 under conditions permitting expression of the monoclonal antibody, and recovering the produced monoclonal antibody from the culture. Item 20. A composition comprising the monoclonal antibody according to any one of items 1 to 15 or the monoclonal antibody produced by the process according to item 19. Item 21. A detection system comprising: a) a first monoclonal antibody that binds to sBCMA; and b) a second monoclonal antibody that binds to sBCMA; wherein binding of the first monoclonal antibody to sBCMA occurs in the presence of a second monoclonal antibody that binds sBCMA, and / or binding of the second monoclonal antibody to sBCMA occurs in the presence of the first monoclonal antibody that binds sBCMA. Item 22. The detection system described in Item 21, wherein the sBCMA has the amino acid sequence set forth in SEQ ID NO: 34. Item 23. The detection system of item 21 or 22, wherein binding of the first monoclonal antibody to sBCMA and binding of the second monoclonal antibody to sBCMA occur in the presence of a third antibody or antibody construct that binds to sBCMA. Item 24. The detection system according to Item 23, wherein the third antibody or antibody construct binds to epitope cluster 3 of BCMA, preferably to epitope cluster 3 of human BCMA, and preferably has the amino acid sequence set forth in SEQ ID NO: 35. Item 25. The detection system according to any one of Items 21 to 24, wherein the first monoclonal antibody and / or the second monoclonal antibody comprises a rabbit VH region and / or a rabbit VL region. Item 26. The first monoclonal antibody and / or the second monoclonal antibody have a serotype of about ≦10 -7 M, ≦10 -8 M, ≦10 -9 M or ≦10 -1026. The detection system according to any one of items 21 to 25, having an affinity (KD) for sBCMA of M. Item 27. The first monoclonal antibody is a) comprising a VH region comprising VH-CDR1 shown in SEQ ID NO: 1, VH-CDR2 shown in SEQ ID NO: 2, and VH-CDR3 shown in SEQ ID NO: 3, and a VL region comprising VL-CDR1 shown in SEQ ID NO: 4, VL-CDR2 shown in SEQ ID NO: 5, and VL-CDR3 shown in SEQ ID NO: 6; b) a VH region comprising a VH-CDR1 represented by SEQ ID NO: 11, a VH-CDR2 represented by SEQ ID NO: 12, and a VH-CDR3 represented by SEQ ID NO: 13, and a VL region comprising a VL-CDR1 represented by SEQ ID NO: 14, a VL-CDR2 represented by SEQ ID NO: 15, and a VL-CDR3 represented by SEQ ID NO: 16; or c) binds to the same sBCMA epitope as an antibody of a) or b) or competes for binding to sBCMA with an antibody of a) or b); and / or The second monoclonal antibody is d) a VH region comprising VH-CDR1 as set forth in SEQ ID NO: 21, VH-CDR2 as set forth in SEQ ID NO: 22, and VH-CDR3 as set forth in SEQ ID NO: 23, and a VL region comprising VL-CDR1 as set forth in SEQ ID NO: 24, VL-CDR2 as set forth in SEQ ID NO: 25, and VL-CDR3 as set forth in SEQ ID NO: 26; or 27. The detection system according to any one of items 21 to 26, wherein e) the antibody binds to the same sBCMA epitope as the antibody of d) or competes with the antibody of d) for binding to sBCMA. Item 28. The first monoclonal antibody is a) comprises a VH region as set forth in SEQ ID NO: 7 or 17; b) comprises a VL region as set forth in SEQ ID NO: 8 or 18; c) comprising a VH region as set forth in SEQ ID NO: 7 and a VL region as set forth in SEQ ID NO: 8; d) comprising a VH region as set forth in SEQ ID NO: 17 and a VL region as set forth in SEQ ID NO: 18; or e) binds to the same sBCMA epitope as an antibody of c) or d) or competes for binding to sBCMA with an antibody of c) or d); and / or The second monoclonal antibody is f) comprises a VH region as set forth in SEQ ID NO: 27; g) comprises a VL region as set forth in SEQ ID NO: 28; h) comprising a VH region as set forth in SEQ ID NO: 27 and a VL region as set forth in SEQ ID NO: 28; or 28. The detection system of item 27, wherein i) the antibody binds to the same sBCMA epitope as the antibody of h) or competes with the antibody of h) for binding to sBCMA. Item 29. The detection system according to any one of Items 21 to 28, wherein the first monoclonal antibody and / or the second monoclonal antibody is an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody or an IgA antibody, preferably an IgG antibody, such as an IgG1 antibody, an IgG2 antibody, an IgG3 antibody or an IgG4 antibody. Item 30. The detection system according to any one of Items 21 to 29, wherein the first monoclonal antibody is used as a capture antibody and the second monoclonal antibody is used as a detection antibody, or the first monoclonal antibody is used as a detection antibody and the second monoclonal antibody is used as a capture antibody. Item 31. The monoclonal antibody according to any one of items 1 to 15 or the detection system according to any one of items 21 to 30, - detecting sBCMA in a sample; - quantitating sBCMA in a sample; - diagnosing a disease associated with sBCMA or increased sBCMA; - stratify patients diagnosed with sBCMA or diseases associated with increased sBCMA; - monitoring the progression of a disease associated with sBCMA or increased sBCMA; or - monitoring response to treatment of sBCMA or diseases associated with increased sBCMA For use. Item 32. A method for detecting and / or quantifying sBCMA in a sample, comprising: (a) using a monoclonal antibody (or an antibody construct) according to any one of items 1 to 15 or using a detection system according to any one of items 21 to 30 for determining the content of sBCMA in a sample; (b) the content of sBCMA determined in step (a), (i) a predefined value for sBCMA content; (ii) the content of sBCMA determined in a control sample; or (iii) the content of sBCMA determined in a sample obtained from the same source or subject at an earlier time point; A process of comparing with The method includes: Item 33. A method for diagnosing a disease associated with sBCMA or increased sBCMA, comprising: (a) using a monoclonal antibody (or an antibody construct) according to any one of items 1 to 15 or using a detection system according to any one of items 21 to 30 for determining the content of sBCMA in a sample; (b) the content of sBCMA determined in step (a), (i) a predefined cut-off value for sBCMA content that indicates the absence of such disease, or (ii) the content of sBCMA determined in a control sample representative of the absence of such disease; A process of comparing with wherein a higher content of sBCMA determined in step (a) compared to (i) a pre-defined cut-off value or (ii) the content of sBCMA determined in a control sample indicates the presence of sBCMA or a disease associated with increased sBCMA. Item 34. A method for monitoring the progression of a disease associated with sBCMA or increased sBCMA or for monitoring the response to a treatment of a disease associated with sBCMA or increased sBCMA, comprising: (a) using a monoclonal antibody (or antibody construct) according to any one of items 1 to 15 or using a detection system according to any one of items 21 to 30 for determining the content of sBCMA at a first time point in a biological sample obtained from a subject diagnosed with such a disease; (b) using the monoclonal antibody (or antibody construct) according to any one of items 1 to 15 or using the detection system according to any one of items 21 to 30 for determining the content of sBCMA in a biological sample obtained from the subject at a second time point or after the treatment; (c) comparing the content of sBCMA determined in step (a) with the content of sBCMA determined in step (b); wherein a higher content of sBCMA determined in step (a) compared to the content of sBCMA determined in step (b) indicates that the disease is progressing, and / or a lower content of sBCMA determined in step (a) compared to the content of sBCMA determined in step (b) indicates that the disease is going into remission or that the disease is responding to treatment. Item 35. The use according to item 31 or the method according to any one of items 32 to 34, wherein the sample is a biological sample, preferably a human biological sample, such as a serum sample, a plasma sample, a blood sample, a bone marrow sample, a tissue sample or a supernatant obtained from a cell culture of bone marrow mononuclear cells or peripheral blood mononuclear cells. Item 36. The use according to item 31 or 35 or the method according to any one of items 32 to 35, wherein the sample is obtained from a human subject, preferably a human subject suspected of having or having a disease associated with sBCMA or increased sBCMA or a subject undergoing treatment for a disease associated with sBCMA or increased sBCMA. Item 37. The use according to any one of items 31, 35 or 36, or the method according to any one of items 32 to 36, wherein the disease is selected from the group consisting of multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma (extramedullary plasmacytoma, extramedullary multiple myeloma), plasmacytoma, plasma cell leukemia, Waldenström's macroglobulinemia (lymphoplasmacytic lymphoma), smoldering myeloma (smoldering multiple myeloma), chronic lymphocytic leukemia (CLL), primary CNS lymphoma (PCNSL) and B-cell non-Hodgkin's lymphoma (B-NHL).

[0156] As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to a "reagent" includes one or more of such various reagents, and reference to a "method" includes reference to equivalent steps and methods known to those of skill in the art that may be modified or substituted for the method described herein.

[0157] Unless otherwise indicated, the term "at least" preceding a series of elements should be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by this invention.

[0158] The term "and / or", wherever used in this specification, includes the meanings "and", "or" and "any other combination of the elements connected by said term".

[0159] The terms "about" or "approximately" as used herein mean within ±20%, preferably within ±15%, more preferably within ±10%, and most preferably within ±5% of a given value or range, including specific values, for example, "about 50" includes the value "50."

[0160] Throughout this specification and the claims, unless the context otherwise requires, the words "comprise" and variations such as "comprises" and "comprising" will be understood to imply the inclusion of a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integers or steps. As used herein, the term "comprise" may be replaced with the terms "containing" or "including" or, as sometimes used herein, the term "having."

[0161] As used herein, "consisting of" excludes any component, step, or ingredient not specified in the claim component. As used herein, "consisting essentially of" does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.

[0162] In each instance herein, any of the terms "comprising," "consisting essentially of," and "consisting of" may be replaced with one of the other two terms.

[0163] The above description and the following examples provide exemplary configurations, but it should be understood that the invention is not limited to the particular methodology, techniques, protocols, materials, reagents, substances, etc. described herein, as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the invention, which is defined solely by the claims. Aspects of the invention are provided in the independent claims. Some optional features of the invention are provided in the dependent claims.

[0164] All publications and patents cited throughout the text of this specification, whether supra or infra, including all patents, patent applications, scientific publications, manufacturer's specifications, instructions, etc., are hereby incorporated by reference in their entirety. Nothing herein should be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention. To the extent that material incorporated by reference is inconsistent or inconsistent with the present specification, the present specification will take precedence over any such material.

[0165] A better understanding of the present invention and its advantages will be obtained from the following examples, which are provided for illustrative purposes only and are not intended, and should not be construed, as limiting the scope of the invention in any way. EXAMPLES

[0166] Example 1: Generation of rabbit monoclonal anti-sBCMA sandwich mAbs The aim of this endeavour was to generate a non-interfering antibody pair ("sandwich pair") for detecting sBCMA even in the presence of therapeutic anti-BCMA antibodies or antibody constructs (e.g. "Ther-Ab1" or "Ther-Ab2") or other antibodies / antibody constructs (e.g. those with identical or similar CDRs and / or binding to the same epitope within sBCMA). Ther-Ab2 is a CD3xBCMA bispecific, half-life extended antibody construct previously shown to bind to epitope cluster 3 (SEQ ID NO:35) of the BCMA extracellular domain (see WO 2013 / 072406). Ther-Ab1 has an IgG1 format and has here been shown to interfere with detection / quantification of BCMA using a commercially available ELISA kit (R&D systems goat polyclonal antibody BCMA capture and detection, see Figure 1A). Ther-Ab1 is disclosed in WO 2014 / 089335 as having the following amino acid sequences: VH-CDRs (SEQ ID NOs: 4 to 6), VL-CDRs (SEQ ID NOs: 106 to 108), VH (SEQ ID NO: 206), and VL (SEQ ID NO: 240) of WO 2014 / 089335.

[0167] In a next step, approximately 400 XenoMouse® hybridomas were generated against BCMA and tested positive in an ELISA assay for binding to BCMA. However, screening of these XenoMouse® hybridomas did not identify any Ther-Ab1 sandwich antibodies, even when using a different Octet format (see FIG. 1B).

[0168] In a later step, a rabbit immunization campaign was performed with chimeric proteins containing BCMA as immunogen. Rabbit sera were screened for sandwich binding with Ther-Ab1. The following materials were used: Streptavidin biosensor (Pall ForteBio 18-5021) Biotinylated BCMA Ther-Ab1 Rabbit terminal blood ·Rabbit irrelevant IgG (Abcam 172730) 384-well flat-bottom black polypropylene microplate (Greiner BioOne 781209) ·96-well flat-bottom black polypropylene microplate (Greiner BioOne 655209) ForteBio Octet HTX Octet assay buffer (10mM Tris, 0.1% Triton, 150mM NaCl, 1mM CaCl2, 0.1mg / mL BSA, pH 7.4).

[0169] All samples were prepared in Octet assay buffer. Ther-Ab1 and rabbit irrelevant IgG were prepared at 10 μg / ml, and Biotin-BCMA was prepared at 0.15 μg / ml. Samples were placed in 384-well plates at 80 μL / well. When using 96-well plates, biosensors were pre-incubated in 200 μL of Octet buffer.

[0170] The assay was set up on a ForteBio HTX to run as follows (see also FIG. 1C): 1. Baseline (octet buffer, 60 seconds) 2. Loading (Biotin-BCMA, 300 sec) 3. Association (Ther-Ab1, 900 seconds) 4. Baseline (octet buffer, 60 seconds) 5. Sandwich antibody (rabbit serum or irrelevant IgG antibody, 300 sec).

[0171] The reporter point analysis function on the Octet was used to determine the binding signal at the antibody sandwich step. The antibody sandwich step was first aligned to zero so that the calculated signal was absolute. The Ther-Ab1 sandwich antibody was confirmed in rabbit serum by the Octet.

[0172] After further enrichment of rabbit-derived cells that bind BCMA, another Octet BCMA sandwich assay was performed with Ther-Ab2 to confirm the presence of the Ther-Ab2 sandwich antibody.

[0173] Finally, three new rabbit anti-sBCMA antibodies were identified (sBCMA-mAb1, sBCMA-mAb2 and sBCMA-mAb3) and their heavy and light chain variable regions were sequenced. These antibodies were characterized in more detail using the assays described below.

[0174] Example 2: Characterization of rabbit monoclonal anti-sBCMA sandwich mAbs in the Octet assay a) Purified recombinant antibodies sBCMA-mAb1 and sBCMA-mAb2 were screened for sandwich binding with Ther-Ab2. The following materials were used: Anti-huFc (kinetic) biosensor (Pall ForteBio 18-5064) ·BCMA Ther-Ab2 Unrelated (CD3 x target-X) bispecific antibody construct (which differs from Ther-Ab2 only in the target-binding domain) Unpurified but quantified sBCMA-mAb2 supernatant sBCMA-mAb1 ·Rabbit irrelevant IgG (Abcam 172730) 384-well slanted bottom black polypropylene microplate (ForteBio 18-5080) ·96-well flat-bottom black polypropylene microplate (Greiner BioOne 655209) ForteBio Octet HTX Octet assay buffer (10mM Tris, 0.1% Triton, 150mM NaCl, 1mM CaCl2, 0.1mg / mL BSA, pH 7.4).

[0175] All samples were prepared in Octet assay buffer. Test antibodies, rabbit irrelevant IgG and irrelevant bispecific antibody constructs were prepared at 5 μg / mL. BCMA was prepared at 2 μg / mL. Samples were placed at 60 μL / well in 384-well plates. When using 96-well plates, biosensors were pre-incubated in 200 μL of Octet buffer.

[0176] The assay was set up on a ForteBio HTX to run as follows: 1. Baseline (Octet buffer, 60 seconds) 2. First antibody loading (Ther-Ab2 or irrelevant bispecific antibody construct, 120 sec) 3. Activation (BCMA, 120 seconds) 4. Baseline (Octet buffer, 60 sec) 5. Second antibody (sBCMA-mAb2, sBCMA-mAb1 or irrelevant rabbit antibody, 120 sec).

[0177] The reporter point analysis function on the Octet was used to determine the binding signal at the second antibody step. The second antibody step was first aligned to zero so that the calculated signal was absolute. The results are shown in Figure 2. The rabbit anti-sBCMA antibodies sBCMA-mAb1 and sBCMA-mAb2 were found to sandwich with Ther-Ab2.

[0178] b) A further Octet assay was carried out according to the assay described in Example 2a), demonstrating that antibodies sBCMA-mAb1 and sBCMA-mAb2 share a similar sBCMA epitope with the following settings (competition assay): 1. Baseline (Octet Buffer) 2. Loading of the first antibody (Ther-Ab2) 3.Activation (BCMA) 4. Baseline (Octet Buffer) 5. Rabbit Antibody 1 (sBCMA-mAb1, sBCMA-mAb2 or an irrelevant rabbit IgG antibody, see Table 2 below) 6. Rabbit Antibody 2 (sBCMA-mAb2, sBCMA-mAb1 or an irrelevant rabbit IgG antibody, see Table 2 below).

[0179] [Table 2]

[0180] c) Remarkably, only one of the 226 rabbit antibodies against sBCMA (i.e., sBCMA-mAb3) was able to sandwich with Ther-Ab2 and sBCMA-mAb1. This was demonstrated in an Octet sandwich assay involving the following steps: 1. Capture B-Goat Anti-Rabbit Fc on SA Octet Sensor 2. Binding sBCMA-mAb1 3. Block the sensor with irrelevant IgG 4. Binding Ther-Ab2 or irrelevant bispecific antibody construct + / - BCMA 5. Bind sBCMA-mAb3.

[0181] The results are shown in Figure 3. These were confirmed in further assays using sBCMA-mAb1 and sBCMA-mAb3 as purified recombinant antibodies and involving an Octet sandwich step as follows: 1. Capture B-Goat Anti-Rabbit Fc on SA Octet Sensor 2. Binding sBCMA-mAb1 3. Block the sensor with irrelevant IgG 4. Bind + / - BCMA 5. Binding Ther-Ab2 6. Bind sBCMA-mAb3.

[0182] The results are shown in Figure 4. Replacing sBCMA-mAb1 with irrelevant IgG in step 2 did not give any signal in the assay after further addition of BCMA, Ther-Ab2 and sBCMA-mAb3 (negative control).

[0183] d) The sBCMA / Ther-Ab2 sandwich was demonstrated to be optimal (in terms of minimal interference by Ther-Ab2) for capture with sBCMA-mAb1 and detection with sBCMA-mAb3, using the following settings: 1. Capture B-Goat Anti-Rabbit Fc on SA Octet Sensor 2. Binding sBCMA-mAb1 (Setting 1) or sBCMA-mAb3 (Setting 2) 3. Block the sensor with irrelevant IgG 4. Bind + / - BCMA 5. Binding Ther-Ab2 6. Bind sBCMA-mAb3 (Setting 1) or sBCMA-mAb1 (Setting 2).

[0184] The difference in signal between the setup with and without BCMA was more pronounced when using sBCMA-mAb1 as the capture antibody compared to using sBCMA-mAb3 as the capture antibody.

[0185] Example 3: Affinity determination of rabbit monoclonal anti-sBCMA sandwich mAbs Binding affinity profiles were determined for the following rabbit monoclonal anti-sBCMA sandwich mAbs: - sBCMA-mAb1 (stock concentration 1.43mg / ml) - sBCMA-mAb2 (stock concentration 2.251mg / ml) - sBCMA-mAb3 (stock concentration 0.78mg / ml).

[0186] Experiments were performed using a Biacore 3000 (GE Healthcare) at 25° C. The running buffer was HBS-P (10 mM HEPES, pH 7.4, 150 mM NaCl, 0.05% Surfactant P-20) + 0.1% BSA and kinetics were performed at high flow rate (100 μl / min). 10 mM glycine, pH 1.7 was used for regeneration.

[0187] Surface preparation: Goat anti-rabbit IgG Fc (Jackson Research Prod.#111-005-046) was diluted 1 / 20 in Na acetate, pH 5 and covalently coupled to sample and reference Fc (Fc1) on a CM5 sensor chip using amine coupling. Individual mAbs were diluted in HBS-P+0.1% BSA and captured with Fc2, 3 or 4 at 0.3 μg / ml for kinetic analysis of binding to sBCMA.

[0188] Interaction parameters: sBCMA (1.19 mg / ml stock) was injected as analyte at 600 nM, 300 nM, 150 nM, 75 nM, 37.5 nM, 18.8 nM and 9.4 nM with the 75 nM concentration run twice to measure reproducibility. Association rates were monitored over 2.5 min. Dissociation times were 20 min to determine more accurate kinetics for mAbs with slower off-rates. Data were double background referenced in that both the reference Fc and 0 nM analyte concentration were subtracted from the data. A 1:1 Langmuir binding model with mass transfer was used from the Biacore evaluation software.

[0189] The results are shown in FIG. 5 and Table 3 below.

[0190] [Table 3]

[0191] [Table 4]

[0192]

Table 5

Claims

1. a) a first monoclonal antibody that binds to sBCMA; b) a second monoclonal antibody that binds to sBCMA; and A detection system comprising: The first monoclonal antibody comprises: i) a VH region comprising a VH-CDR1 represented by SEQ ID NO:1, a VH-CDR2 represented by SEQ ID NO:2, and a VH-CDR3 represented by SEQ ID NO:3, and a VL region comprising a VL-CDR1 represented by SEQ ID NO:4, a VL-CDR2 represented by SEQ ID NO:5, and a VL-CDR3 represented by SEQ ID NO:6; or ii) a VH region comprising a VH-CDR1 represented by SEQ ID NO: 11, a VH-CDR2 represented by SEQ ID NO: 12, and a VH-CDR3 represented by SEQ ID NO: 13, and a VL region comprising a VL-CDR1 represented by SEQ ID NO: 14, a VL-CDR2 represented by SEQ ID NO: 15, and a VL-CDR3 represented by SEQ ID NO: 16; The second monoclonal antibody comprises: A VH region including VH-CDR1 shown in SEQ ID NO: 21, VH-CDR2 shown in SEQ ID NO: 22, and VH-CDR3 shown in SEQ ID NO: 23, and a VL region including VL-CDR1 shown in SEQ ID NO: 24, VL-CDR2 shown in SEQ ID NO: 25, and VL-CDR3 shown in SEQ ID NO: 26, A detection system wherein the binding of the first monoclonal antibody to sBCMA also occurs in the presence of the second monoclonal antibody that binds to sBCMA, and / or the binding of the second monoclonal antibody to sBCMA also occurs in the presence of the first monoclonal antibody that binds to sBCMA.

2. The detection system of claim 1 , wherein the sBCMA has an amino acid sequence as set forth in SEQ ID NO:

34.

3. The detection system of claim 1 or 2, wherein the binding of the first monoclonal antibody to sBCMA and the binding of the second monoclonal antibody to sBCMA also occurs in the presence of a third antibody or antibody construct that binds to sBCMA.

4. The detection system according to any one of claims 1 to 3, wherein the first monoclonal antibody and / or the second monoclonal antibody comprises a rabbit VH region and / or a rabbit VL region.

5. The first monoclonal antibody and / or the second monoclonal antibody have a mAb concentration of about ≦10 -7 M,≦10 -8 M,≦10 -9 M or ≦10 -10 The detection system according to any one of claims 1 to 4, having an affinity (KD) for sBCMA of M.

6. The first monoclonal antibody comprises: a) comprises a VH region as set forth in SEQ ID NO: 7 or 17; b) comprises a VL region as set forth in SEQ ID NO: 8 or 18; c) comprising a VH region as set forth in SEQ ID NO: 7 and a VL region as set forth in SEQ ID NO: 8; d) comprising a VH region as set forth in SEQ ID NO: 17 and a VL region as set forth in SEQ ID NO: 18; or e) competes with the antibody of c) or d) for binding to sBCMA; and / or The second monoclonal antibody comprises: f) comprises a VH region as set forth in SEQ ID NO:27; g) comprises a VL region as set forth in SEQ ID NO:28; h) comprising a VH region as set forth in SEQ ID NO:27 and a VL region as set forth in SEQ ID NO:28; or i) competes with the antibody of h) for binding to sBCMA; A detection system according to claims 1 to 5.

7. The detection system according to any one of claims 1 to 6, wherein the first monoclonal antibody and / or the second monoclonal antibody is an IgG antibody, an IgD antibody, an IgE antibody, an IgM antibody or an IgA antibody.

8. The detection system according to claim 7 , wherein the first monoclonal antibody and / or the second monoclonal antibody is an IgG1 antibody, an IgG2 antibody, an IgG3 antibody or an IgG4 antibody.

9. The detection system according to any one of claims 1 to 8, wherein the first monoclonal antibody is used as a capture antibody and the second monoclonal antibody is used as a detection antibody, or the first monoclonal antibody is used as a detection antibody and the second monoclonal antibody is used as a capture antibody.

10. - detecting sBCMA in a sample; - quantitating sBCMA in a sample; - diagnosing diseases associated with sBCMA or increased sBCMA; - stratifying patients diagnosed with sBCMA or a disease associated with increased sBCMA; - monitoring the progression of a disease associated with sBCMA or increased sBCMA; or - monitoring the response to treatment of diseases associated with sBCMA or increased sBCMA The detection system according to any one of claims 1 to 9 for:

11. 1. A method for detecting and / or quantitating sBCMA in a sample, comprising: (a) using a detection system according to any one of claims 1 to 9 to determine the content of sBCMA in a sample; (b) the content of sBCMA determined in step (a) (i) a predefined value for the sBCMA content; (ii) the content of sBCMA determined in a control sample; or (iii) the content of sBCMA determined in a sample obtained from the same source or subject at an earlier time point; A process of comparing with The method includes:

12. 1. A method for providing data to aid in the diagnosis of sBCMA or a disease associated with increased sBCMA, comprising: (a) using a detection system according to any one of claims 1 to 9 to determine the content of sBCMA in a sample; (b) the content of sBCMA determined in step (a) (i) a predefined cut-off value for the sBCMA content that indicates the absence of the disease; or (ii) the content of sBCMA determined in a control sample representative of the absence of the disease; A process of comparing with wherein a higher content of sBCMA determined in step (a) compared to the predefined cut-off value in (i) or the content of sBCMA determined in the control sample in (ii) indicates the presence of sBCMA or a disease associated with increased sBCMA.

13. 1. A method for monitoring the progression of a disease associated with sBCMA or increased sBCMA, or for monitoring the response to treatment of sBCMA or increased sBCMA, comprising: (a) using a detection system according to any one of claims 1 to 9 to determine the content of sBCMA at a first time point in a biological sample obtained from a subject diagnosed with said disease; (b) using the detection system according to any one of claims 1 to 9 to determine the content of sBCMA in a biological sample obtained from the subject at a second time point or after treatment; (c) comparing the amount of sBCMA determined in step (a) with the amount of sBCMA determined in step (b); wherein a higher content of sBCMA determined in step (a) compared to the content of sBCMA determined in step (b) indicates that the disease is progressing, and / or a lower content of sBCMA determined in step (a) compared to the content of sBCMA determined in step (b) indicates that the disease is going into remission or that the disease is responding to the treatment.

14. The detection system of claim 10 , wherein the sample is a biological sample.

15. The detection system of claim 14 , wherein the biological sample is a human biological sample.

16. The detection system of claim 15, wherein the human biological sample is a serum sample, a plasma sample, a blood sample, a bone marrow sample, a tissue sample or a supernatant obtained from a cell culture of bone marrow mononuclear cells or peripheral blood mononuclear cells.

17. The detection system according to any one of claims 10 or 14 to 16, wherein the sample is obtained from a human subject.

18. The detection system of claim 17, wherein the sample is obtained from a human subject suspected of having or having a disease associated with sBCMA or increased sBCMA, or a subject undergoing treatment for a disease associated with sBCMA or increased sBCMA.

19. The detection system according to any one of claims 10 or 14 to 18, wherein the disease is selected from the group consisting of multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma (extramedullary plasmacytoma, extramedullary multiple myeloma), plasmacytoma, plasma cell leukemia, Waldenstrom's macroglobulinemia (lymphoplasmacytic lymphoma), smoldering myeloma (smoldering multiple myeloma), chronic lymphocytic leukemia (CLL), primary CNS lymphoma (PCNSL) and B-cell non-Hodgkin's lymphoma (B-NHL).

20. The method according to any one of claims 11 to 13, wherein the sample is a biological sample.

21. 21. The method of claim 20, wherein the biological sample is a human biological sample.

22. 22. The method of claim 21, wherein the human biological sample is a serum sample.

23. The method of any one of claims 11 to 13 or 20 to 22, wherein the sample is obtained from a human subject.

24. The method of claim 23, wherein the sample is obtained from a human subject suspected of having or having a disease associated with sBCMA or increased sBCMA, or a subject undergoing treatment for a disease associated with sBCMA or increased sBCMA.

25. 25. The method of any one of claims 12, 13 or 20-24, wherein the disease is selected from the group consisting of multiple myeloma, relapsed and / or refractory multiple myeloma, heavy chain multiple myeloma, light chain multiple myeloma, extramedullary myeloma (extramedullary plasmacytoma, extramedullary multiple myeloma), plasmacytoma, plasma cell leukemia, Waldenström's macroglobulinemia (lymphoplasmacytic lymphoma), smoldering myeloma (smoldering multiple myeloma), chronic lymphocytic leukemia (CLL), primary CNS lymphoma (PCNSL) and B-cell non-Hodgkin's lymphoma (B-NHL).

Citation Information

Patent Citations

  • Binding molecules for BCMA and CD3

    JP2018050627A

  • BCMA (CD269 / tnfrsf17)-binding proteins

    JP2018087190A